| Protocol No. |
Title |
| 08271 |
The TrialNet Natural History Study of the Development of Type 1 Diabetes |
| 140074 |
Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry |
| 2007NT080 |
Magnetic Resonance Imaging of the Prostate at 7 Tesla |
| 2009UC147-2 |
I-SPY 2 TRIAL -Investigation of Serial Studies to Predict your Therapeutic Response
with Imaging and Molecular Analysis 2 |
| 2011NTLS157 |
Use of Pap test samples to study human diseases |
| 2013NTUC039 |
MT2013-19R: BMT Long-Term Follow-up Study -2 |
| 2014NTLS069 |
Personalized mouse models of chemotherapy resistance in ovarian cancer
|
| 2014NTLS071 |
Family-based studies of susceptibility to early onset disease |
| 2015NTLS048 |
Adaptive Interventions for Smoking Cessation in Lung Cancer Screening Programs |
| 2016LS132 |
MT2016-11 :Autologous Stem Cell Transplant In Patients with Hodgkin Lymphoma (HL)
and Non-Hodgkin Lymphomas (NHL) |
| 2016LS161D |
MT2017-17: Alpha/Beta T Cell Depleted (alpha/beta TCD)
Hematopoietic Cell Transplantation in Patients with Inherited Bone Marrow Failure
(BMF) Disorders |
| 2016NTLS035-LCNS |
Solid Tumor Cancer Specimen Bank - Lung Cancer Never Smoker |
| 2016NTLS083 |
Developing Evidence-Based Criteria for Initiating Treatment for Neurofibromatosis
Type 1 Associated Optic Pathway Glioma |
| 2016NTLS151 |
Cytomegalovirus Status and Adaptive Natural Killer Cells in Ovarian Cancer: A Pilot
Study |
| 2016NTLS163 |
Development Of A Clinical Precision Medicine Program In Ovarian Cancer As A Paradigm
For 21st Century Tailored-Health Care Solutions |
| 2017CG139 |
COG AALL1621 - A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND#133494)
in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic
Leukemia (B-ALL) |
| 2017LS006 |
HM2017-24 : Phase I/II Study of Nivolumab in Combination with Ruxolitinib in Relapsed
or Refractory Classical Hodgkin Lymphoma: BTCRC-HEM-027 |
| 2017NTLS106 |
Attitudes, Perceptions and Psychosocial Determinants of Cancer Screening among East
African Communities |
| 2018CG049 |
MT2018-19: COG ANBL1531 - A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG)
or ALK Inhibitor Therapy Added to Intensive Therapy for Children with Newly Diagnosed
High-Risk Neuroblastoma (NBL) (IND# 134379) |
| 2018CG089 |
COG AGCT1531 - A Phase 3 Study of Active Surveillance for Low Risk and a Randomized
Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients
with Germ Cell Tumors |
| 2018CG118 |
COG AGCT1532 - A Randomized Phase 3 Trial of Accelerated versus Standard BEP Chemotherapy
for Patients with Intermediate and Poor-risk Metastatic Germ Cell Tumors |
| 2018NTLS045 |
MT2018-05R Clinical Outcomes in Hematopoietic Cell Transplantation or Cell Therapy |
| 2018NTLS123 |
Characterization of Coagulation plus Cell Activation and Adhesion in Myeloproliferative
Neoplasms |
| 2018NTLS135 |
Observational Study of Exposure to Environmental Toxicants Among Firefighters |
| 2018NTUC068 |
Understanding Causes of Outcome Disparities in Adolescents and Young Adults (AYA)
with Acute Lymphoblastic Leukemia (ALL)
Short Title: AYA ALL |
| 2019CG218 |
COG AALL1732: A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#:
772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for
High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy |
| 2019LS010 |
A Randomized Double Blind Phase II Trial of Restorative Microbiota Therapy (RMT) or
Placebo in Combination with Durvalumab (MEDI4736) and Tremelimumab With Chemotherapy
in Treatment Naïve Advanced or Metastatic Adenocarcinoma Non-Small Cell Lung Cancer |
| 2019NTLS027 |
MT2019-01: Adrenoleukodystrophy National Registry Study (ALD) and Biobank |
| 2019NTLS030 |
The role of cytomegalovirus and inflammation on patient symptoms and outcomes in ovarian
cancer |
| 2019NTLS052 |
Sample Collection for Environmental Exposure |
| 2019NTLS126 |
GLNE 007 Evaluation of Stool Based Markers for the Early Detection of Colorectal Cancers
and Adenomas |
| 2019NTLS211 |
Understanding the impact of Female Genital Mutilation on Anorectal and Willingness
to Undergo Colorectal Cancer Screening Amongst Somali Migrants to the US |
| 2019NTLS213 |
Skin Cancer Risk in Patients with Autoimmune Connective Tissue Disease Treated with
lmmunosuppressive Medications: a retrospective cohort study |
| 2020CG051 |
COG ACNS1833 - A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine
versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated
Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis
Type 1 (NF1) |
| 2020CG131 |
MT2020-35 - COG AAML1831 - A Phase 3 Randomized Trial for Patients With De Novo AML
Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO,
and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations
|
| 2020CG187 |
COG AREN1921 - Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT)
and Relapsed Favorable Histology Wilms Tumors (FHWT) |
| 2020IS117 |
A Multicenter Observational Study of GammaTile Surgically Targeted Radiation Therapy
(STaRT) in Intracranial Brain Neoplasms |
| 2020LS048 |
Peripheral neuropathy, neural density, and chemotherapy; a prospective cohort trial |
| 2020LS159 |
Mujeres Avanzando a la Sobrevida (Women Going Forward in Survival): a Prospective
Breast Cancer Cohort Study in Honduras |
| 2020UC077 |
National Registry of Pediatric Cancer Patients Diagnosed with COVID-19 |
| 2021CG038 |
COG AALL1821 - A Phase 2 Study of Blinatumomab (NSC# 765986, IND# 147294) in Combination
with Nivolumab (NSC # 748726, IND# 147294), a Checkpoint Inhibitor of PD-1, in B-ALL
Patients Aged >/=1 to < 31 Years Old with First Relapse |
| 2021CG040 |
A non-randomized prospective clinical trial comparing the non-inferiority of salpingectomy
to salpingo-oophorectomy to reduce the risk of ovarian cancer among BRCA1 carriers
(SOROCk) |
| 2021CG156 |
PEPN2011 - A Phase 1/2 Study of Tegavivint (IND#156033, NSC#826393) in Children, Adolescents,
and Young Adults with Recurrent or Refractory Solid Tumors, Including Lymphomas and
Desmoid Tumors |
| 2021CG176 |
A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical
Cancer (ROCC trial) |
| 2021IS148 |
HM2021-31: A Phase 1b Open-Label Study to Evaluate the Safety and Anti-cancer Activity
of Loncastuximab Tesirine in Combination with Other Anti-cancer Agents in Patients
with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) |
| 2021IS173 |
A Phase 1, First in Human, Dose-Escalation Study of TORL-1-23 in Participants with
Advanced Cancer |
| 2021LS034 |
Telehealth study assessing the removal of filter ventilation on smoking behavior and
biomarkers |
| 2021LS041 |
Development of Protein Biomarkers from Urine of Prostate Cancer Patients |
| 2021LS061 |
MT2021-08: Phase II, Open-Label, Prospective Study of T Cell Receptor Alpha/Beta Depletion
(A/B TCD) Peripheral Blood Stem Cell (PBSC) Transplantation for Children and Adults
with Hematological Malignancies |
| 2021LS099 |
Increasing HPV vaccination coverage among pediatric, adolescent, and young adult (PAYA)
cancer survivors: A multilevel intervention |
| 2021LS105 |
Phase I Study of Peptide Alarm Therapy (PAT) Administered by Intratumoral Injection
with a PD-1/PD-L1 Inhibitor in Patients with Solid Tumor Cancers Who Have Failed Two
Prior Therapies |
| 2021LS140 |
Phase I Clinical Trial of iPSC-Based Therapy (MyoPAXon) for Duchenne Muscular Dystrophy |
| 2021LS162 |
The effects of cigarette smoking and alcohol on DNA damage in the oral cavity |
| 2021UC056 |
Single-Arm Phase II Study of Carboplatin and Mirvetuximab Soravtansine in First-Line
Treatment of Patients receiving Neoadjuvant Chemotherapy with Advanced-Stage Ovarian,
Fallopian Tube or Primary Peritoneal Cancer who are Folate Receptor positive |
| 2022CG008 |
PEPN2111 - A Phase 1/2 Trial of CBL0137 (NSC# 825802, IND# 155843) in Patients with
Relapsed or Refractory Solid Tumors including CNS Tumors and Lymphoma |
| 2022CG021 |
COG APAL2020SC - Pediatric Acute Leukemia (PedAL) Screening Trial Developing New Therapies
for Relapsed Leukemias |
| 2022CG084 |
ACNS1821: A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed
Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG) |
| 2022CG090 |
AOST2031: A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management
of Pulmonary Metastases in Patients With Osteosarcoma |
| 2022CG116 |
NRG-GY026: A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined with either
Trastuzumab and Hyaluronidase-Oysk (Herceptin Hylecta) or Pertuzumab, Trastuzumab,
and Hyaluronidase-Zzxf (Phesgo) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma
or Carcinosarcoma |
| 2022IS066 |
A Phase 1b Open-Label Multicenter Study of OP-1250 (Palazestrant) in Combination with
the CDK4/6 Inhibitor Ribociclib, with the PI3K Inhibitor Alpelisib, or with the mTOR
inhibitor
Everolimus in Adult Subjects with Advanced and/or Metastatic ER Positive, HER2 Negative
Breast Cancer |
| 2022IS103 |
MT2025-36: Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination
with Pembrolizumab Versus Investigator s Choice in HLA-A*02:01-positive Participants
with Previously Treated Advanced Melanoma (TEBE-AM) |
| 2022LS030 |
A Phase I Study of a Tropism Modified Conditionally Replicative Adenovirus Vector
(RGDCRAdCOX2F) for Endoscopic, Direct-Tumor Delivery in Pancreatic Adenocarcinoma |
| 2022LS040 |
A Window of Opportunity Trial of Mirdametinib plus Vorinostat for NF1 Associated,
Malignant Peripheral Nerve Sheath Tumor; MPNST |
| 2022LS089 |
MT2022-49: Early identification of cognitive side-effects of immunotherapy |
| 2022LS100 |
Time toxicity of cancer: the time demands of cancer-related activities and their impact
on well-being and quality of life |
| 2022LS127 |
Investigating Vaped Phenanthrene Biomarkers in Former Smokers |
| 2022LS146 |
MT2022-52: Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity
Conditioning (RIC) with Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological
Diseases |
| 2022LS170 |
Project SHINE (Sleep Health INitiative for Equity): Culturally informing a sleep extension
intervention for African American adults |
| 2022LS174 |
MT2022-60: A phase II study of Pembrolizumab+ BEAM conditioning regimen before autologous
stem cell transplant (ASCT) followed by pembrolizumab maintenance in patients of relapsed
classic Hodgkin lymphoma |
| 2022LS182 |
Application of Engineered Tumor Infiltrating Lymphocytes (TILs) in Pediatric Osteosarcoma |
| 2022UC044 |
ITCC-101/APAL2020D - A randomized phase 3 trial of fludarabine/cytarabine/gemtuzumab
ozogamicin with or without venetoclax in children with relapsed AML (A subtrial of
the PedAL/EuPAL relapsed acute leukemia master protocol) |
| 2022UC072 |
MT2022-35: Black Box- Hematopoietic Stem Cell Transplant Complications |
| 2022UC108 |
A Randomized Phase II Study Comparing Sequential High dose Testosterone and Enzalutamide
to Enzalutamide alone in Asymptomatic Men with Castration Resistant Metastatic Prostate
Cancer |
| 2022UC123 |
MT2022-44 Analysis of Autoinflammation in Chronic Granulomatous Disease Patients Undergoing
Hematopoietic Cell Transplantation or Gene Therapy (PIDTC 6908) |
| 2022UC124 |
MT2022-45 Primary Immune Regulatory Disorders (PIRD): Longitudinal Study of Clinical
Presentation, Treatment and Outcomes |
| 2023CG022 |
COG ARST2032: A Prospective Phase 3 Study of Patients with Newly Diagnosed Very Low-risk
and Low-risk Fusion Negative Rhabdomyosarcoma |
| 2023CG028 |
AOST2032; A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor
Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma |
| 2023CG042 |
Quality of Life and Impact of Disease in People with Sickle Cell Disease Over Time |
| 2023CG058 |
A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab
Versus Treatment of Physician s Choice in Patients With Triple Negative Breast Cancer
Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05) |
| 2023CG077 |
AHOD2131, A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy
with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I
and II Classic Hodgkin Lymphoma |
| 2023CG091 |
OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR
After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy |
| 2023EX070 |
MT2023-12: Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene
autoleucel (cilta-cel) Out-of-Specification (OOS) in patients with Multiple Myeloma |
| 2023IS002 |
MT2023-46: A Phase 3, multicenter, randomized, open-label, parallel group, treatment
study to assess the efficacy and safety of the lifileucel (LN-144, autologous tumor-infiltrating
lymphocytes [TIL]) regimen in combination with pembrolizumab compared with pembrolizumab
monotherapy in participants with untreated, unresectable or metastatic melanoma |
| 2023IS017 |
MT2023-34 A Safety and Effectiveness Registry Study of Patients with B-Thalassemia
Treated with Betibeglogene Autotemcel |
| 2023IS027 |
MT2023-06: A CLINICAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF LERIGLITAZONE IN
ADULT MALE SUBJECTS WITH CEREBRAL ADRENOLEUKODYSTROPHY |
| 2023IS032 |
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Optune® (TTFields,
200 kHz) Concomitant with Maintenance Temozolomide and Pembrolizumab Versus Optune®
Concomitant with Maintenance Temozolomide and Placebo for the Treatment of Newly Diagnosed
Glioblastoma (EF-41/KEYNOTE D58) |
| 2023IS037 |
Phase I/II, Multi-Center, Open-Label Study of VT3989, Alone or in Combination, in
Patients with Locally Advanced or Metastatic Solid Tumors |
| 2023IS107 |
MT2023-30: A Phase 1 Study of FT825/ONO-8250, an Off-the-Shelf CAR T-Cell Therapy,
With or Without Monoclonal Antibodies, in HER2-Positive or Other Advanced Solid Tumors |
| 2023IS140 |
MT2023-29: Long-term Follow-up of Subjects With Sickle Cell Disease Treated With ExVivo
Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced With a Lentiviral
Vector |
| 2023IS142 |
A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination
with Other Anti-Cancer Therapies in Patients with KRAS, BRAF and Other
Selected RAS/MAPK Mutation-Positive Malignancies |
| 2023IS178 |
MT2023-42: A Phase 1 Study of FT819 in B-Cell Mediated Autoimmune Diseases |
| 2023IS180 |
MT2023-51 A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes
(LN-145) in Patients with Metastatic Non-Small-Cell Lung Cancer |
| 2023IS187 |
A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate
or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer
(mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based
Chemotherapy (OMAHA-003) |
| 2023IS200 |
A Phase 3, Multicenter, Open-label Study to Test the Diagnostic Performance of Copper
Cu 64 PSMA I&T PET/CT in Staging of Men with Newly Diagnosed Unfavorable Intermediate-risk,
High-risk or Very High-risk Prostate Cancer Electing to Undergo Radical Prostatectomy
with Pelvic Lymph Node Dissection
|
| 2023IS205 |
MT2024-05: A Phase I, First in Human Open Label Study to Evaluate the Safety and Tolerability
of TRX103 cell infusion in subjects with hematological malignancies undergoing HLA-mismatched
related or unrelated hematopoietic stem cell transplantation (HSCT) |
| 2023LS024 |
MT2023-05: GTB-3650 (anti-CD16/IL-15/anti-CD33) Tri-Specific Killer Engager (TriKE®)
for the Treatment of High Risk Myelodysplastic Syndromes (MDS) and Refractory/Relapsed
Acute Myeloid Leukemia (AML) |
| 2023LS072 |
MT2023-14: Supporting patients and caregivers during hematopoietic stem cell transplant
(HSCT): What is working, not working and how can we improve? |
| 2023LS079 |
Characterization of Genetically Engineered Tumor Infiltrating Lymphocytes (TIL) in
Adults
Living with Sarcomas |
| 2023LS102 |
Effects of relighting on smoke toxicant deliveries and subjective smoking measures |
| 2023LS109 |
MT2023-24:The Minnesota Biorepository Protocol for biological samples obtained after
Chimeric Antigen Receptor (CAR)-T Cell Therapy |
| 2023LS119 |
Legacy Sample Repository |
| 2023LS145 |
Defining the Immune Landscape of Osteosarcoma at the Single-Cell Level |
| 2023LS160 |
MT2023-38 Monitoring of Immune Reconstitution in Hematopoietic Cell Transplantation
(HCT) and Novel Immunotherapies |
| 2023LS181 |
Effects of tobacco and nicotine cessation on biomarkers |
| 2023LS183 |
HM2023-43: A phase 2 trial of tafasitamab in combination with lenalidomide+rituximab
in treatment-naive follicular lymphoma and marginal zone lymphoma |
| 2023LS213 |
Cervical and Endometrial Cancer Screening in Patients Seeking Gender-Affirming Hysterectomy |
| 2023LS215 |
Development of Tobacco Related Biomarkers |
| 2023LS222 |
Detecting Ovarian Cancer by Analyzing Volatile Organic Compounds (VOCs) in Human Breath |
| 2023UC164 |
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active
Surveillance Suitability as Treatment: a breast cancer prevention pilot study |
| 2024CG068 |
ANBL2131/MT2024-35- A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy
for Children with Newly Diagnosed High-Risk Neuroblastoma |
| 2024CG100 |
DESTINY-Endometrial01: An Open-Label, Sponsor-Blinded, Randomized, Controlled, Multicenter,
Phase III Study of Trastuzumab Deruxtecan (T-DXd) Plus Rilvegostomig or Pembrolizumab
vs Chemotherapy Plus Pembrolizumab as First-Line Therapy of HER2-Expressing (IHC 3+/2+),
Mismatch Repair Proficient (pMMR), Primary Advanced or Recurrent Endometrial Cancer |
| 2024CG113 |
NRG-GU012: Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for
Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)
|
| 2024CG120 |
PEPN2312; A Phase 1 study of GRN163L (Imetelstat, IND# 170891, NSC# 754228) in combination
with fludarabine and cytarabine for patients with acute myeloid leukemia that is in
second or greater relapse or that is refractory to relapse therapy; myelodysplastic
syndrome or juvenile myelomonocytic leukemia in first or greater relapse or is refractory
to relapse therapy |
| 2024CG224 |
ACNS2321; A Phase II Trial Evaluating Chemotherapy followed by Response-Based Reduced
Radiation Therapy for Patients with Central Nervous System Germinomas |
| 2024EX045 |
MT2024-10: Expanded Access Single Patient Use of Brexucabtagene Autoleucel (Tecartus)
OOS for a Patient with Relapsed B Cell Acute Lymphoblastic Leukemia |
| 2024IS036 |
A Phase 1B/2 pan-tumor, open-label study to evaluate the efficacy and safety of ifinatamab
deruxtecan (I-DXD) in subjects with recurrent or metastatic solid tumors (IDeate-Pantumor02) |
| 2024IS038 |
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and
Clinical Activity of GSK5733584 for Injection in Subjects with Advanced Solid Tumors |
| 2024IS050 |
HM2024-36 A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF QUIZARTINIB
ADMINISTERED IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY AND ADMINISTERED
AS MAINTENANCE THERAPY IN ADULT PATIENTS WITH NEWLY DIAGNOSED FLT3-ITD NEGATIVE ACUTE
MYELOID LEUKEMIA |
| 2024IS051 |
MT2024-12: A Phase 1 Study Evaluating BAFFR-targeting CAR T cells for Patients with
Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL) |
| 2024IS055 |
HM2024-18 A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic
Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary
Myelofibrosis |
| 2024IS058 |
A Phase 1B/2, Multicenter, Open-label Study of Ifinatamab Deruxtecan (I-DXd), A B7-
H3 Antibody-Drug Conjugate (ADC), In combination with Atezolizumab with or Without
Carboplatin as First Line Induction or Maintenance, In Subjects with Extensive-Stage
Small Cell Lung Cancer (ES-SCLC) (IDeate-Lung03) |
| 2024IS065 |
A Randomized, Controlled, Multicenter, Phase 3 Clinical Study Comparing Vusolimogene
Oderparepvec in Combination with Nivolumab Versus Treatment of Physician s Choice
in Patients with Advanced Melanoma That Has Progressed on an Anti-PD-1 and an Anti-CTLA-4
Containing Treatment Regimen [IGNYTE-3] |
| 2024IS070 |
A first-in-human, Phase 1/2, open-label, multi-center, dose-escalation, dose-optimization,
and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics,
and anti-tumor activity of PARP1 selective inhibitor, IMP1734, as monotherapy and
in combination in participants with advanced solid tumors |
| 2024IS089 |
A Randomized Phase II Study of Letrozole Versus Observation in Patients with Newly
Diagnosed Uterine Leiomyosarcoma |
| 2024IS099 |
Hybrid Content Confirmation and Cognitive Debriefing Interviews of Patient-Reported
Outcomes in Patients with Recurrent or Advanced Endometrial Cancer |
| 2024IS116 |
A Phase 1a/b Study of ADRX-0405 in Subjects with Select Advanced Solid Tumors |
| 2024IS146 |
A Phase 1, Open-Label, Multicenter Study of JANX007 in Subjects with Metastatic Castration-Resistant
Prostate Cancer |
| 2024IS162 |
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination
with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination
with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated
Locally Advanced or Metastatic Non-Small Cell Lung Cancer |
| 2024IS170 |
A Phase 3 open-label, randomized, active-controlled, multicenter trial to evaluate
the efficacy and safety of orally administered BAY 2927088 compared with standard
of care as a first-line therapy in patients with locally advanced or metastatic non-small
cell lung cancer (NSCLC) with HER2-activating mutations. |
| 2024IS190 |
A Phase Ib open label randomised clinical trial to evaluate safety and efficacy of
BI 770371 in combination with pembrolizumab with or without cetuximab compared with
pembrolizumab monotherapy for the first-line treatment of patients with metastatic
or recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) |
| 2024IS197 |
MT2024-38: A Phase 1/2 Open-Label, Single-Ascending-Dose Study of EN-374, a Helper-Dependent
Adenoviral-Based Gene Therapy, in Participants with X-Linked Chronic Granulomatous
Disease |
| 2024IS202 |
MT2024-42: Phase 1b Dose Expansion/2 Study of NXC-201 for the Treatment of Patients
with Relapsed or Refractory AL Amyloidosis |
| 2024IS205 |
Hypoplasminogenemia: An International RetroSpecTive and PrOspective CohoRt StudY;
HISTORY |
| 2024IS209 |
A Phase 1 Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary
Efficacy of ACE-232 in Patients with Metastatic Castration-Resistant Prostate Cancer
(CRPC) |
| 2024IS211 |
A Randomized, Double-blinded, Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab
for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients
Whose Tumors Demonstrate High PD-L1 Expression (HARMONi-7) |
| 2024IS222 |
HM2025-23: Phase 3 Randomized, Double-Blind, Placebo-controlled Studies Assessing
Ziftomenib in Combination with Either Standard of Care Nonintensive Venetoclax+Azacitidine)
or Intensive (7+3) Therapy in Patients with Untreated NPM1 mutated or KMT2A Rearranged
Acute Myeloid Leukemia |
| 2024IS223 |
A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING
THE EFFICACY AND SAFETY OF INAVOLISIB PLUS A CDK4/6 INHIBITOR AND LETROZOLE VERSUS
PLACEBO PLUS A CDK4/6 INHIBITOR AND LETROZOLE IN PATIENTS WITH ENDOCRINE-SENSITIVE
PIK3CA-MUTATED, HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER (WO45654) |
| 2024LS054 |
Development of a RET-Specific Proteomic Assay from Circulating Tumor Cells in Lethal
Prostate Cancer |
| 2024LS061 |
MT2024-13: First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma |
| 2024LS083 |
MT2024-24: Evaluation of patient-reported outcomes (PRO) for participants treated
with GTB-3650 (anti-CD16/IL-15/anti-CD33) Tri-Specific Killer Engager (TriKE) |
| 2024LS084 |
Evaluation of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKi)
resistance in the tumor tissue of Non-small cell lung cancer (NSCLC) patients |
| 2024LS102 |
ConnectedNest: a digital platform connecting individuals with cancer to social care |
| 2024LS126 |
Randomized Clinical Trial of Culturally Aligned Digital Smoking Cessation Resources
for American Indian Persons |
| 2024LS134 |
Clarke Pilot CRTI; Impact of discrimination/social isolation on cardiovascular health
in breast cancer survivors treated with aromatase inhibitors: link to gut microbiome |
| 2024LS138 |
MT2024-24: A Pilot Study To Determine Risk Factors for Developing Financial Toxicity
in Patients with Hematologic Malignancies Receiving CAR T-Cell Therapy |
| 2024LS139 |
Evaluating Population-Based Strategies for Rural Smoking Cessation |
| 2024LS140 |
MT2024-25: Allogeneic Hematopoietic Stem Cell Transplant for Patients with High Risk
Hemoglobinopathies and Other Red Cell Transfusion Dependent Disorders |
| 2024LS151 |
HM2024-28: A Pilot Study to Investigate the Clinical Utility of Tremoflo Airway Oscillometry
in the Pediatric and Adolescent Population with Pulmonary Pathology or at Risk of
Lung Injury |
| 2024LS157 |
HM2024-29: Phase I/II Clinical Trial of Proteasome Inhibitor in Combination with CPX-351
for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML). |
| 2024LS159 |
Minnesota Cancer Assessment Mobile Program (MCamp) Survey |
| 2024LS181 |
UNderstanding The experience of Ovarian cancer Life after Diagnosis (UNTOLD) study |
| 2024LS187 |
Assessing and Enhancing Survivorship Care in Adolescent and Young Adult Cancer Survivors |
| 2024UC044 |
A Phase 3, open-label, randomized 2-arm study comparing the clinical efficacy and
safety of niraparib with temozolomide in adult participants with newly-diagnosed,
MGMT unmethylated glioblastoma |
| 2024UC145 |
Clinical Characteristics and Factors Influencing Outcomes of Diffuse Hemispheric Glioma,
H3 G34-mutant: A Multi-Institutional Retrospective Cohort Study |
| 2024UC180 |
National Liver Cancer Screening Trial |
| 2025CG008 |
A PHASE III TRIAL OF ONE VS. TWO YEARS OF MAINTENANCE OLAPARIB, WITH OR WITHOUT BEVACIZUMAB,
IN PATIENTS WITH BRCA1/2 MUTATED OR HOMOLOGOUS RECOMBINATION DEFICIENT (HRD+) OVARIAN
CANCER FOLLOWING RESPONSE TO FIRST LINE PLATINUM-BASED CHEMOTHERAPY |
| 2025CG017 |
ALTE22C1, Chronic Health Conditions in Down Syndrome-Associated Acute Leukemia:
The Down Syndrome Phenotyping Acute Leukemia Study in Survivors (DS-PALS Survivors) |
| 2025CG018 |
ALTE2131, An NCORP Phase 3 Study of Triptorelin and Protection of Ovarian Reserve
in Adolescents and Young Adults with Cancer
|
| 2025CG036 |
RANDOMIZED PHASE III TRIAL OF NEOADJUVANT IMMUNOTHERAPY WITH RESPONSE-ADAPTED TREATMENT
VERSUS STANDARD-OFCARE TREATMENT FOR RESECTABLE STAGE III/IV CUTANEOUS SQUAMOUS CELL
CARCINOMA |
| 2025CG084 |
PEPN2415; A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, and
Preliminary Efficacy of AZD1390 (NSC# 852149, IND# 172675) when Combined with Focal
Radiation in Pediatric Patients with High Grade Glioma |
| 2025CG086 |
AALL2321; A Phase 2 Study of Blinatumomab in Combination with Chemotherapy for Infants
with Newly Diagnosed Acute Lymphoblastic Leukemia with Randomization of KMT2A-Rearranged
Patients to Addition of Venetoclax |
| 2025CG088 |
AREN2231; Risk Adapted Treatment of Unilateral Favorable Histology Wilms Tumors (FHWT)
|
| 2025CG102 |
AALL2131; An International Pilot Study of Chemotherapy and Tyrosine Kinase Inhibitors
with Blinatumomab in Patients with Newly-Diagnosed Philadelphia Chromosome-Positive
or ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leukemia |
| 2025CG106 |
Multimodality Therapy with Immunotherapy in Stage I-IIIA Pleural Mesothelioma |
| 2025CG121 |
NRG-BN013: Phase III Trial of Single Fraction Stereotactic Radiosurgery (SRS) versus
Fractionated SRS (FSRS) for Intact Brain Metastases |
| 2025EX172 |
Single Patient Compassionate Use of Autologous iPSC-Derived Myogenic Progenitors (C3-
automyo) for the Treatment of LGMDR1/LGMD2A |
| 2025EX208 |
MT2025-52 INTERMEDIATE-SIZE PATIENT POPULATION EXPANDED ACCESS PROGRAM (EAP) WITH
NON ADVANCED SYSTEMIC MASTOCYTOSIS OR
ADVANCED SYSTEMIC MASTOCYTOSIS PROTOCOL |
| 2025IS031 |
A Phase 1/2 Study of FOG-001 in Participants with Locally Advanced or Metastatic Solid
Tumors (FOG-001-101) |
| 2025IS038 |
A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig Plus Abiraterone
Versus Investigator s Choice in Participants with Chemotherapy-naïve Metastatic Castration
resistant Prostate Cancer |
| 2025IS044 |
A Prospective Low-Interventional Phase 4 Single Arm Study of Ocular Assessments in
Patients Treated with Tivdak® in Recurrent or Metastatic Cervical Cancer |
| 2025IS062 |
A Phase 1b Open-label, Multicenter Study Evaluating the Safety, Tolerability, and
Efficacy of Xaluritamig in Combination with Androgen Receptor Pathway Inhibitors in
Participants with Metastatic Hormone-sensitive Prostate Cancer |
| 2025IS066 |
MT2025-24: A Phase 1, Open-Label Study of FT836, an Off-the-Shelf CAR T-Cell Therapy,
With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced
Solid Tumors |
| 2025IS094 |
A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343),
a T-cell-redirecting Agent Targeting Human Kallikrein 2, + Best Supportive Care Versus
Best Supportive Care for Metastatic Castration-resistant Prostate Cancer |
| 2025IS120 |
IMPACT: A Clinical Investigation on IMproving Peripheral Neuropathy Induced by Anti-Cancer
Drugs with Advanced Compression Technology; A Safety and Efficacy Study |
| 2025IS125 |
Phase I open-label dose escalation trial of BI 3923948 monotherapy and in combination
with an anti-PD-1 mAb in patients with advanced, unresectable and/or metastatic solid
tumors |
| 2025IS126 |
A Global First-in-Human Study in NSCLC, HNSCC, and Solid Tumors with Azirkitug as
a Single
Agent and in Combination(s) with Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan |
| 2025IS177 |
MT2025-50: An Open-label, Multicenter Phase 1/2 Study to Evaluate the Safety and Efficacy
of AB-3028 in Patients with Castration Resistant Prostate Cancer (CRPC) |
| 2025IS200 |
A Phase 1 Study of JNJ-87189401 (PSMA-CD28 Bispecific Antibody) Combined with JNJ-78278343
(KLK2-CD3 Bispecific Antibody) for Advanced Prostate Cancer |
| 2025LS049 |
MT2025-14: A Phase 1a/1b Study of GTB-5550, a Camelid Nanobody TriSpecific Killer
Engager (camB7-H3 TriKE®), in Select Advanced Solid Tumors That Failed Prior Therapy
|
| 2025LS052 |
A Nurse Led Quality Improvement Project Aimed at Identifying Facilitators and Barriers
to Breast Cancer Screening for Female AYA HL and PMBCL Survivors |
| 2025LS162 |
MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity
Conditioning Treosulfan and Fludarabine, with Post-Transplant Cytoxan (PTCy) for the
Treatment of Hematological Diseases |
| 2025UC065 |
HM2025-16: Phase Ib/II Trial of Epcoritamab plus Ibrutinib in Patients with Relapsed/Refractory
Aggressive B-cell Non-Hodgkin Lymphoma. |
| 2026LS003 |
Co-Designing a Low-Burden Mobile Nutrition App Intervention with Breast Cancer Survivors |
| 80802 |
CALGB 80802: PHASE III RANDOMIZED STUDY OF SORAFENIB PLUS DOXORUBICIN VERSUS SORAFENIB
IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC) |
| ANES-2022-31377 |
To Investigate Airway Oxygen Concentrations during Rigid Bronchoscopy Procedures Performed
with High Frequency Jet Ventilation |
| ANES-2023-31691 |
Superficial Cervical Plexus Block for Improved Outcomes in Pediatric Otolaryngologic
Surgery |
| ANES-2023-31918 |
Rectus sheath block with liposomal bupivacaine versus thoracic epidural analgesia
for pain control following pancreatoduodenectomy: a prospective, randomized, non-inferiority
trial |
| ANES-2023-32053 |
Addition of a pectoserratus block to interscalene block in patients undergoing total
shoulder replacement. |
| ANES-2024-33184 |
Effects of Pain on Laboratory Drinking Topography and Daily Drinking in People with
Chronic Temporomandibular Disorder (TMD) Pain |
| ANES-2025-33850 |
Testing a Virtual Reality Echocardiography Simulator for Teaching Perioperative Transesophageal
Echocardiography |
| ANES-2025-33910 |
Characterizing Neuropathic Pain in Individuals Receiving Inpatient Treatment for an
Alcohol Use Disorder |
| ANES-2025-33949 |
FEEDS Trial: Fasting Preprocedurally in Enteral Nutrition: Evaluation of Divergent
Approaches in Secure Airway |
| ANES-2025-34223 |
Heat Mapping Abdominal Fascial Plane Blocks |
| ANES-2025-34341 |
Moni-Patch Temperature Monitoring Patch System Clinical Accuracy Validation |
| ANES-2025-34568 |
Evaluation of a Novel Airway Opening Technique Using High-Fidelity Airway Mannequins |
| CBS-2024-33212 |
GC-PRO Intervention |
| CMRR-2017-21895 |
Imaging of DBS targets at 7T MRI |
| CMRR-2023-32199 |
CMRR Healthy Participant Registry |
| CMRR-2024-32922 |
Natural History of and Genetic Modifiers in Spinocerebellar Ataxias |
| CMRR-2026-34296 |
Developing faster cardiac MRI protocols |
| CSH-2023-31874 |
Partners for Pain & Wellbeing: A Randomized Trial of Community Supported Complementary
and Integrative Health Self Management for Back Pain |
| CV-2014-20799 |
National Biological Sample and Data Repository for Pulmonary Arterial Hypertension
|
| CV-2014-22223 |
Minnesota Pulmonary Hypertension Repository Study |
| CV-2014-22442 |
Cardiac Sarcoidosis Consortium |
| CV-2017-25423 |
Pulmonary Hypertension Association Registry (PHAR) |
| CV-2019-27489 |
Prediction Modeling in Heart Failure Patients |
| CV-2019-28111 |
Patterns of Cardiovascular Disease: Characteristics, Predictors and Outcomes |
| CV-2019-28423 |
The predictive value of preoperative CPX in Left Ventricular Assist Device and Orthotopic
Heart Transplant outcomes |
| CV-2020-28665 |
Long Term Outcomes and Quality of Life in Patients with Out of Hospital Cardiac Arrest |
| CV-2022-30951 |
JIT -- Left Ventricular Physiological Effects of Veno-Arterial Extracorporeal Membrane
Oxygenation support During Cardiogenic Shock |
| CV-2022-31523 |
Immunologic Basis of Cardiovascular Disease after COVID-19 |
| CV-2022-31579 |
Physical Rehabilitation for Older Patients with Acute Heart Failure with Preserved
Ejection Fraction (REHAB-HFpEF) |
| CV-2023-32230 |
Effect of Empagliflozin on Left Atrial Function in Adults at Risk for Heart Failure |
| CV-2023-32312 |
A Phase 3, Double-Blind, Randomized, Placebo-Controlled
Study of Levosimendan in Pulmonary Hypertension Patients
With Heart Failure With Preserved Left Ventricular Ejection
Fraction (PH-HFpEF); LEVEL: LEVosimendan to Improve
Exercise Limitation in Patients With PH-HFpEF |
| CV-2024-32928 |
Testing the feasibility of a clinic-based assessment of exercise-induced maximum heart
rate and heart rate recovery in adults without cardiovascular disease |
| CV-2024-33094 |
REFORM-HF.
REducing Fluid Overload using Renal Independent systeM in Heart Failure Patients |
| CV-2024-33527 |
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the
Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants
Living With Obesity and Heart Failure |
| CV-2025-33847 |
Early Feasibility Study of the NORM System in Heart Failure Patients |
| DEM-2023-31500 |
Senolytics To slOw Progression of Sepsis |
| DENT-2020-29282 |
Brain Connectivity Patterns in Chronic Temporomandibular Joint Disorders |
| DENT-2022-31055 |
Co-morbid Trigeminal Neuralgia and TMD |
| DENT-2022-31080 |
Identification of biomarkers in chronic TMD patients |
| DENT-2023-31099 |
Pharmacogenomic Testing to Inform Analgesic Selection for Dental-related Acute Pain
Management: An Application of Precision Medicine Methods in Dentistry |
| DENT-2025-34002 |
Development and Validation of an MRI-Compatible Jaw Metabolic Stressor Task_Study1 |
| DENT-2026-34879 |
Single-Cell and Spatial Transcriptomic Profiling of Human Cleft Palate Tissue to Identify
Therapeutic Targets |
| DERM-2019-26638 |
Transition of Care in Patients with Epidermolysis Bullosa: Survey Study |
| DERM-2020-28674 |
Hidradenitis Suppurativa Registry |
| DERM-2020-28745 |
Protocol Number: TARGET-DERM;A 5-year Longitudinal Observation
Therapy for Immune-Mediated;Inflammatory Skin Conditions |
| DERM-2020-29149 |
Registry and Biological Specimen Repository for Disorders of Genome Repair |
| DERM-2021-27916 |
Use of Continuous Wave Doppler to assess Vascular Malformations in Pediatric Dermatology |
| DERM-2021-29370 |
Measuring Alopecia Areata Patient-Reported Psychosocial Outcomes: Scale Development
and Validation Part B |
| DERM-2021-30229 |
Posterior lamella reconstruction by periosteal flap: a retrospective study |
| DERM-2022-30819 |
Evaluation of Microbiota Transplant Therapy in Patients with Alopecia Areata |
| DERM-2022-31369 |
Global Prevalence of Hidradenitis Suppurativa |
| DERM-2022-31378 |
Hidradenitis Suppurativa Prospective Observational Registryand Biospecimen Repository-
HS PROGRESS |
| DERM-2022-31562 |
MTT for H.S. Investigate whether restoring normal gut microbiome composition with
cMTT influences the relative overabundance of anaerobic bacteria and microbial diversity
of the skin in patients with HS |
| DERM-2023-31404 |
Analysis of Peripheral Nerve Function in Patients with Frontal Fibrosing Alopecia |
| DERM-2023-31719 |
Bullying in Pediatric Alopecia Areata: A Survey Study |
| DERM-2023-31787 |
H.S. Registry Analysis |
| DERM-2023-31959 |
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy,
Safety, and Pharmacokinetics of Baricitinib in Children from 6 Years& Less than 18
Years of Age with Alopecia Areata |
| DERM-2023-32014 |
Testing Of Alternatives For Dark Hair Dyes In Patients With Proven Sensitization To
Para-Phenylenediamine |
| DERM-2023-32083 |
Objective validation of drug allergies- Evaluation of results from comprehensive testing
in a novel drug allergy clinic |
| DERM-2023-32345 |
Protocol M23-716: A Phase 3 randomized, placebo-controlled, double-blind program
to evaluate efficacy and safety of upadacitinib in adult and adolescent subjects with
severe alopecia areata |
| DERM-2024-32369 |
Coach Sun Safety Education in Youth Sports Camps |
| DERM-2025-33772 |
A PHASE 3, EXTERNAL AND SYNTHETIC PLACEBO-CONTROLLED RANDOMIZED STUDY WITH DOSE-UP
FOR NON-RESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100
MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH
ALOPECIA AREATA |
| DERM-2025-33780 |
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study
of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa Topical Ruxolitinib
Evaluation in Hidradenitis Suppurativa (TRuE-HS1) |
| DERM-2025-33838 |
MT2025-21: A Phase 1 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer
(CAR NK) Cell Therapy, in Subjects with Immune-Mediated Diseases |
| DERM-2025-33946 |
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-dose Study to
Evaluate the Efficacy and Safety of VDPHL01 in Female Subjects with Androgenetic Alopecia |
| DERM-2025-34120 |
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate
Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults with
Chronic Spontaneous Urticaria Inadequately Controlled bySecond Generation H1-Antihistamines |
| DMED-2024-33328 |
Perceptions and Expressions of Depression and Anxiety among Indigenous Women of the
Rural Peruvian Amazon |
| DMED-2025-33636 |
Cannabidiol (CBD) and Stress Response: Psychobiological Mechanisms |
| ENT-2020-28903 |
Vibrotactile stimulation of the larynx to treat unexplained chronic cough |
| ENT-2021-29988 |
Characterization of spleen motion and anatomy using imaging and sensors |
| ENT-2022-30531 |
Measurement of Upper Aerodigestive Tract Pressures During Phonation |
| ENT-2022-31139 |
PIOGLITAZONE-METFORMIN COMBINATION TREATMENT FOR HIGH RISK ORAL PRENEOPLASIA |
| ENT-2023-30344 |
Profile analysis of carcinogen-DNA adducts in oral cells of cigarette smokers and
squamous cell carcinoma of the head and neck _ Multisite
|
| ENT-2023-32271 |
Ecological Momentary Assessment of Muscle Tension Dysphonia |
| ENT-2024-33112 |
Assessment of usability and satisfaction with a take-home device presenting sound
and body stimulation for back pain |
| ENT-2025-33821 |
Myofunctional Therapy for Obstructive Sleep Apnea |
| ENT-2025-34418 |
Satisfaction and usability assessment of a take-home device for tinnitus |
| ENT-2026-34616 |
Acoustic analysis of voice, speech, and breath sounds in subglottic stenosis |
| FMCH-2022-31326 |
Multi-level predictors of structural racism and discrimination and associations with
health and well-being across the life course in diverse families |
| FMCH-2023-32305 |
Modifying Progesterone and Estradiol Levels to Prevent Postpartum Cigarette Smoking
Relapse and Reduce Secondhand Smoke Exposure in Infants and Children |
| FMCH-2024-32739 |
Gender Identity Measurement In Early School Aged Children |
| FSCN-2023-31797 |
A dual-arm randomized cross-over trial to assess wHether ORganic grass-fed cow MEat
increases Levels of SCFAs and SCFA-producing bacteria, and reduces inflammatory type
2 diabetes biomarkers including A1c |
| FSCN-2025-33495 |
Personalized diet-induced changes in the gut microbiome and breast cancer risk |
| FVCTS-2023-SGNDV-001-KN-D74 |
An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination
with Pembrolizumab Versus Chemotherapy in Subjects with Previously Untreated Locally
Advanced or Metastatic Urothelial Carcinoma that Expresses HER2 (IHC 1+ and Greater) |
| FVCV-2023-HERMES |
Effects of ziltivekimab versus placebo on morbidity and mortality in patients with
heart failure with mildly reduced or preserved ejection fraction and systemic inflammation. |
| FVCV-2024-BALANCEDHF |
A Phase III, Randomised, Double-blind Study to Evaluate the Effect of Balcinrenone/Dapagliflozin,
Compared With Dapagliflozin, on the Risk of Heart Failure Events and Cardiovascular
Death in Patients With Heart Failure and Impaired Kidney Function |
| FVCV-2025-AZURECVOT |
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to
Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with
Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First
ASCVD Event |
| FVCV-2025-CONFORM |
An Evaluation of the Safety and Effectiveness of the Conformal CLAAS System for Left
Atrial Appendage Occlusion |
| FVCV-OCEANAPREEVENT-2025 |
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran
Use to Prevent First Major Cardiovascular Events in Participants with Elevated Lipoprotein(a) |
| FVFT-2025-BALANCE4MOBILITY |
Balance4Mobility: Effects of Walkasins Use on Clinical Outcomes of Gait and Balance
Function in Individuals with Peripheral Neuropathy and Balance Problems – A
Randomized Control Trial |
| FVFT-2025-SAMSUNGAFIB |
AFib Feature Data Collection and Validation Study |
| FVMMCORC-2020-S1703 |
RANDOMIZED NON-INFERIORITY TRIAL COMPARING OVERALL SURVIVAL OF PATIENTS MONITORED
WITH SERUM TUMOR MARKER DIRECTED DISEASE MONITORING (STMDDM) VERSUS USUAL CARE IN
PATIENTS WITH METASTATIC HORMONE RECEPTOR POSITIVE HER-2 NEGATIVE BREAST CANCER |
| FVMMCORC-2022-EA2176 |
A Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in
Treatment-Naïve Metastatic Anal Cancer Patients |
| FVMMCORC-2022-EA5182 |
Randomized Phase III Study of Combination AZD9291 (osimertinib) and Bevacizumab versus
AZD9291 (osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant
Non-Small Cell Lung Cancer (NSCLC) |
| FVMMCORC-2022-NRG-BN011 |
NRG-BN011: A Phase III Trial of Lomustine-Temozolomide Combination
Therapy Versus Standard Temozolomide in Patients with Methylated MGMT
Promoter Glioblastoma |
| FVMMCORC-2022-NRG-BR007RG |
A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative
Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score
Less Than or Equal to 18 Breast Cancer |
| FVMMCORC-2022-NRG-GY019 |
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole
Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous
Carcinoma of the Ovary or Peritoneum |
| FVMMCORC-2022-NSABP-C-14 |
CORRECT-MRD II: Second Colorectal Cancer Clinical Validation Study to Predict Recurrence
Using a Circulating Tumor DNA Assay to Detect Minimal Residual Disease |
| FVMMCORC-2022-S1706 |
A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently With
Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer |
| FVMMCORC-2022-WF1901 |
Internet-delivered Management of Pain Among Cancer Treatment Survivors |
| FVMMCORC-2023-A022102 |
RANDOMIZED PHASE III TRIAL OF MFOLFIRINOX +/- NIVOLUMAB VS. FOLFOX +/- NIVOLUMAB FOR
FIRST-LINE TREATMENT OF METASTATIC HER2-NEGATIVE GASTROESOPHAGEAL ADENOCARCINOMA |
| FVMMCORC-2023-EAA181 |
Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized
Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous
Transplantation |
| FVMMCORC-2023-NRG-CC010 |
A PHASE III TRIAL OF THE IMPACT OF SENTINEL LYMPH NODE
MAPPING ON PATIENT REPORTED LOWER EXTREMITY LIMB
DYSFUNCTION IN ENDOMETRIAL CANCER |
| FVMMCORC-2023-S1925 |
S1925, “Randomized, Phase III Study of Early Intervention with Venetoclax and
Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in
Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic
Leukemia / Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study.” |
| FVMMCORC-2023-S2302 |
Pragmatica-Lung: A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128)
Plus Pembrolizumab (MK-3475; NSC 776864) Versus Standard of Care for Participants
Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung
Cancer |
| FVMMCORC-2023-URCC16070 |
Treatment of Refractory Nausea |
| FVMMCORC-2023-URCC21038 |
Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective
Cohort Study of Cancer Survivors Treated With Anti-PD-1/Anti-PD-L1 Immunotherapy in
a Community Oncology Setting |
| FVMMCORC-2024-A012103 |
OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR
After Neoadjuvant Chemotherapy With Checkpoint Inhibitor Therapy |
| FVMMCORC-2024-NRGGY028 |
NRG-GY028: A PHASE IB AND RANDOMIZED PHASE II TRIAL OF
MEGESTROL ACETATE WITH OR WITHOUT IPATASERTIB IN
RECURRENT OR METASTATIC ENDOMETRIOID ENDOMETRIAL
CANCER |
| FVMMCORC-2024-S2206 |
S2206: Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) plus
Chemotherapy versus Chemotherapy Alone for Adults with MammaPrint
Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal
Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer |
| FVMMCORC-2024-SGNDV005 |
A Phase 2 Basket Study of Disitamab Vedotin in Adult Subjects With Previously Treated,
Locally-Advanced Unresectable or Metastatic Solid Tumors That Express HER2 |
| FVMMCORC-2025-A012301 |
A Randomized, Phase III Clinical Trial of Low‐Dose Tamoxifen for Selected Patients
with Molecular Low-risk Early‐Stage Breast Cancer. |
| FVMMCORC-2025-BELLWAVE-011 |
A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator's
Choice of Ibrutinib or Acalabrutinib) in Participants With Untreated Chronic Lymphocytic
Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011) |
| FVMMCORC-2025-CAMBRIA-2 |
CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety
of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader)
vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment
for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk
of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence
of Disease |
| FVMMCORC-2025-EAQ211 |
Social Genomic Mechanisms of Health Disparities Among Adolescent and Young Adult (AYA)
Survivors of Hodgkin and Non-Hodgkin Lymphoma |
| FVMMCORC-2025-EAQ221CD |
Improving Medication Adherence in Metastatic Breast Cancer Using a Connected Customized
Treatment Platform (CONCURxP) |
| FVMMCORC-2025-ELEGANT |
Elacestrant Versus Standard Endocrine Therapy in Women and Men With Node-positive,
Estrogen Receptor-positive, HER2-negative, Early Breast Cancer With High Risk of Recurrence-A
Global, Multicenter, Randomized, Open-label Phase 3 Study |
| FVMMCORC-2025-ES2021-05 |
Specimen Collection Study to Evaluate Biomarkers in Subjects with Cancer |
| FVMMCORC-2025-M25-231 |
A Single-Arm, Phase 2 Study of Neoadjuvant Carboplatin and Mirvetuximab Soravtansine
in Subjects with FRα-Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian
Tube or Primary Peritoneal Cancer |
| FVMMCORC-2025-PRISM-1 |
A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Trial of Quemliclustat
and Chemotherapy Versus Placebo and Chemotherapy in Patients With Treatment-Naive
Metastatic Pancreatic Ductal Adenocarcinoma |
| FVMMCORC-2025-S2013 |
Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study |
| FVMMCORC-2025-TRITON |
A Phase IIIb, Randomized, Multicenter, Open-label Study to Assess the Efficacy of
Durvalumab Plus Tremelimumab Versus Pembrolizumab in Combination With Platinum-Based
Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients
With Non-Squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1,
or KRAS (TRITON). |
| FVMMCORC-2025-WF2304 |
Complementary Options for Symptom Management In Cancer (COSMIC): Assessing Benefits
and Harms of Cannabis and Cannabinoid Use Among a Cohort of Cancer Patients Treated
in Community Oncology Clinics |
| GI-2018-27358 |
SpHincterotomy for Acute Recurrent Pancreatitis (SHARP) Trial |
| GI-2019-27691 |
Biopsy Associated Microbiome |
| GI-2019-27850 |
Automated, Endoscopic Mucosal Disease Activity Scoring for Ulcerative Colitis |
| GI-2019-28228 |
Corrona Inflammatory Bowel Disease (IBD) Registry |
| GI-2021-30033 |
RCT01437: Proactive infliximab optimization using a pharmacokinetic dashboard versus
standard of care in patients with inflammatory bowel disease: The OPTIMIZE Trial |
| GI-2022-30547 |
A novel partial-enteral nutrition protocol to improve nutrition status of adult patients
experiencing a Crohn's disease flare and starting new immunologic therapy |
| GI-2022-30940 |
Compassionate use of domperidone for patients with gastrointestinal motility disorders.
|
| GI-2022-31460 |
Dietary optimization of microbiome recovery following fecal microbiota transplantation |
| GI-2022-31466 |
Fecal biomarkers in discordant Clostridioides difficile lab testing |
| GI-2023-31858 |
The women with inflammatory Bowel Disease and Motherhood: A Prospective Registry |
| GI-2023-32220 |
CD4 T cell response to COVID vaccination |
| GI-2023-32528 |
Antigen-specific T cells and the gut microbiome in celiac disease |
| GI-2024-33127 |
Standardized Microbiota Transplant Therapy in Crohn's Disease |
| GI-2024-33432 |
The Useful Registry of Donors |
| GI-2024-33481 |
LIAISON Calprotectin HD Clinical Performance Validation |
| GIM-2019-27913 |
Identification and Management of Hepatitis C at an FQHC |
| GIM-2025-34307 |
Identifying early-stage barriers and facilitators to implementing the Mobile Advanced
Rural Care Hub (MARCH) Program |
| HOT-2021-30499 |
ADVANCE Cardiovascular Disease (CVD) |
| HOT-2022-30204 |
A pilot study testing the efficacy, safety, and feasibility of Restorative Microbiota
Therapy (RMT) in patients with refractory immune-checkpoint inhibitor-related colitis
|
| HOT-2022-31276 |
Efficacy of a Pill-Dispensing System to Increase Disposal of Unused Opioids and to
Reduce Refills after Cancer-Related Surgery |
| HOT-2022-31308 |
Management of Anticoagulation around Delivery: a VENUS Prospective Cohort Study |
| HOT-2022-31518 |
EFC17574: A Phase 3, single-arm, multicenter, multinational, open label, one-way crossover
study to investigate the efficacy and safety of fitusiran prophylaxis in male participants
aged >= 12 years with severe hemophilia A or B, with or without inhibitory antibodies
to factor VIII or IX |
| HOT-2023-32600 |
Evaluation of the tumor microenvironment in myeloma lytic lesions and its impact on
treatment |
| HOT-2024-32825 |
Efgartigimod Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP) |
| ICD-2024-33463 |
Measurement of task-evoked infant brain activity using fMRI |
| IDIM-2019-27395 |
Effect of N-803 on B Cell Follicles in Antiretroviral Treated HIV Disease |
| IDIM-2020-28516 |
Investigation of Persistent HIV Immune Stimulation in Lymphoid Tissues During Therapy
as a Cause of Sustained Immune Activation |
| IDIM-2022-31098 |
Expanded Access IND Protocol: Use of Tecovirimat (TPOXX) for Treatment of Human Orthopoxvirus
Infections |
| IDIM-2023-31585 |
Longitudinal assessment of the diversity and drug resistance of the gut microbiome
before and after liver transplantation |
| IDIM-2023-31815 |
CLINPRT-7: Intermediate Patient Population Expanded Access Protocol for MBP134 for
Patients with Sudan Virus Disease (SVD) |
| IDIM-2023-32285 |
Zepto Lifes Proposal for Retrospective Convenience
Samples Collaboration with Dr. Youngs Team |
| IDIM-2023-32364 |
Effectiveness of Screening and Decolonization of S. aureus to Prevent S. aureus Surgical
Site Infections in Surgery Outpatients |
| IDIM-2024-32897 |
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF VE303 FOR PREVENTION
OF RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION:
THE RESTORATIVE303 STUDY |
| IDIM-2024-32935 |
A randomized, double-blind, placebo- controlled study of LMN-201 for prevention of
C. difficile infection recurrence (RePreve) |
| IDIM-2024-33154 |
An interventional efficacy and safety Phase 3 double-blind 2-arm study to investigate
IV followed by oral fosmanogepix compared with IV caspofungin followed by oral fluconazole
in adult participants with candidemia and/or invasive candidiasis. |
| IDIM-2024-33178 |
A Phase 2 Multiple Dose Study to Evaluate the Efficacy and Safety of PUL-042 Inhalation
Solution in Reducing Lower Respiratory Tract Complications in Patients with Hematologic
Malignancies and Recipients of Hematopoietic Stem Cell Transplantation (HSCT) with
Documented Viral Infections with Parainfluenza Virus (PIV), Human Metapneumovirus
(hMPV) or Respiratory Syncytial Virus (RSV) |
| IDIM-2024-33364 |
Phase 1b/2a, Randomized, Double-blind Study to Investigate Safety, Tolerability, PK,
PD, and Preliminary Efficacy of Oral Administration of SNIPR001 in Patients with Hematologic
Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplantation Receiving
Fluoroquinolone Prophylaxis and Harboring Fluoroquinolone-Resistant Escherichia coli
Pre-Transplant |
| IDIM-2024-33403 |
CLINPRT-6: An Intermediate Patient Population Expanded Access Protocol for MBP091
for Patients with Marburg Virus Disease (MVD) |
| IDIM-2025-33840 |
An interventional Phase 3, open-label, two-cohort study to investigate the efficacy
and safety of fosmanogepix in adult patients with invasive mold infections caused
by Aspergillus spp., Fusarium spp., Lomentospora prolificans, Mucorales fungi, or
other multidrug resistant molds |
| KIN-2022-31329 |
teleABLE: Adapting a Behavioral Activation-Based Intervention to Reduce Post-Stroke
Sedentary Behavior Using Telehealth (Formative Phase) |
| KIN-2025-34093 |
Characterizing Balance and Postural Control in Children with Autism Using Virtual
Reality Technology |
| KIN-2025-34212 |
Dose-Response Effects of Inspiratory Muscle Strength Training on Blood Pressure and
Vascular Function |
| KIN-2025-34388 |
Functional neural network changes after vibro-tactile stimulation in laryngeal dystonia |
| KIN-2026-34308 |
Physical Activity Engagement Among Postpartum Individuals: A Mixed Methods Study of
Recommendations and Behaviors. |
| KIN-2026-34866 |
Identifying Impairments in Bilateral Coordination in Individuals Post-Stroke |
| LMP-2022-29026 |
ApheresUS Pilot Study |
| LMP-2026-34842 |
Development of genome wide analysis methods for clinical genomics applications |
| MED-2019-27772 |
Outcomes in Acquired Hemophilia A |
| MED-2020-29410 |
Adolescent and Parent Perspectives on Weight Management Approaches for Adolescents
with Obesity |
| MED-2022-30228 |
A feasibility study of topical cannabinoids for treatment of aromatase inhibitor-associated
musculoskeletal syndrome (AIMSS) in women with hormone receptor-positive breast cancer
(CanAroma) |
| MED-2022-30316 |
Time Restricted Eating as a Viable Alternative to Caloric Restriction for Treating
Hyperglycemia in a Population with Type 2 (T2DM) diabetes |
| MED-2022-30904 |
Single dose liposomal amphotericin for asymptomatic cryptococcal antigenemia |
| MED-2022-31096 |
Development of novel screening methods for Cushing's disease |
| MED-2022-31407 |
Predicting and preventing patient deterioration |
| MED-2023-32038 |
Feasibility Study of Fasting Program for Individuals with T1DM |
| MED-2023-32321 |
FAM (Follower, Action Plan, and Remote Monitoring) Intervention to Reduce Severe Hyperglycemia
in Adults with Type 1 Diabetes Mellitus at Risk for Diabetic Ketoacidosis (Aim 3) |
| MED-2024-31907 |
Individualized Diabetes Education Assisted by CGM (IDEA-CGM) |
| MED-2024-32696 |
Hypertension Identification using mobile Health Outreach ProjEct 2 (HI HOPE 2) |
| MED-2024-32816 |
Bionic Pancreas in CFRD: A Randomized Trial of the Insulin-only Bionic Pancreas in
Cystic Fibrosis Related Diabetes |
| MED-2024-32819 |
Closed Loop and Education for hypoglycemia Awareness Restoration (CLEAR) |
| MED-2024-32954 |
Non-Invasive Sleep and Circadian Rhythm Assessment Pre- and Post-surgery in Cushing
Disease |
| MED-2024-33450 |
PREvention of Cardiovascular and DiabEtic kidNey disease in Type 2 Diabetes (PRECIDENTD) |
| MED-2024-33530 |
SPECTRUM: Studying the Presence of CFRD Complications with Thoughtful Recruitment
(SPeCTRuM) |
| MED-2025-33566 |
DEciphering CIrculating SIgnatures Of Infected Pancreatic Necrosis (DECISION) |
| MED-2025-33589 |
Fastomics: Metabolic and Therapeutic Effects of Prolonged Fasting (2025) |
| MED-2025-34071 |
At-home Ultrasound Localized Therapy for Rheumatoid Arthritis Study |
| MEDCHEM-2022-31071 |
Cooked Meat and Prostate DNA Damage |
| MIDB-2022-31246 |
Characterizing the Natural History of Fragile X Syndrome to Inform the Development
of Intervention Outcome Measures |
| MNCCTN013 |
Endocrine Therapy-Induced Alopecia Natural History Evaluation |
| MNCCTN027 |
Topical cannabidiol (CBD) for the treatment of chemotherapy-induced peripheral neuropathy:
a randomized placebo-controlled pilot trial |
| MNCCTN032 |
Reishi Mushroom Extract for fatigue and/or arthralgias in patients with breast cancer
on aromatase inhibitors: a randomized phase II MNCCTN trial |
| MNCCTN037 |
Phase III Study of Ginseng for Cancer Related Fatigue |
| NEPH-2019-28024 |
NEPTUNE: The Nephrotic Syndrome Study Network - RDCRN Protocol 6801 |
| NEPH-2022-30962 |
Minnesota KPMP CKD and Resilient Diabetes Recruiting Site |
| NEPH-2023-32084 |
MT2024-07:A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous
CD19-specific Chimeric Antigen Receptor T cells (CABA-201) in Subjects with Active
Systemic Lupus Erythematosus (RESET-SLE) |
| NEPH-2023-32118 |
A multicenter, randomized, double-blind, parallel group, placebo-controlled study
to evaluate the efficacy and safety of iptacopan (LNP023) in idiopathic immune complex
mediated membranoproliferative glomerulonephritis (IC-MPGN). |
| NEPH-2024-32815 |
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy
and Safety of Ravulizumab in Adult Participants with Immunoglobulin A Nephropathy
(IgAN) |
| NEPH-2024-32860 |
The Women Kidney Program |
| NEPH-2024-33379 |
Use of Artificial Intelligence to Improve Nephrology Fellow Education |
| NEPH-2025-33482 |
A Study to Determine the Prevalence and Clinical Characteristics Associated With PKD1
Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease (ADPKD) |
| NEPH-2025-33626 |
An open-label study to assess the efficacy and safety of extended TARPEYO® (delayed-release
budesonide capsules) treatment in adult patients with primary IgA nephropathy who
have completed 9 months of TARPEYO® 16 mg once daily treatment in real-world clinical
practice |
| NEPH-2025-33674 |
A Phase 2a, Open-label, Single-arm Study to Evaluate the Efficacy, Safety, and Pharmacokinetics
of VX-407 in Subjects with Autosomal Dominant Polycystic Kidney Disease Who Have a
Subset of PKD1 Gene Variants |
| NEPH-2025-33812 |
CureGN: Cure Glomerulonephropathy Network |
| NEPH-2025-33829 |
Kidney Precision Medicine Project (KPMP) Ancillary Study: Functional Magnetic Resonance
Imaging to Identify High-risk Chronic Kidney Disease Phenotypes |
| NEPH-2025-33843 |
An open-label, non-randomized extension study to evaluate the long-term efficacy,
safety and tolerability of iptacopan (LNP023) in C3 glomerulopathy or idiopathic immune-complex-
membranoproliferative glomerulonephritis |
| NEUR-2019-28159 |
Anticoagulation in Intracerebral Hemorrhage (ICH) Survivors for Stroke Prevention
and Recovery |
| NEUR-2019-28388 |
Plasticity of motor systems in early stage Parkinson's disease |
| NEUR-2020-28530 |
A Prospective, Long Term Registry of Patients with a Diagnosis of Spinal Muscular
Atrophy |
| NEUR-2020-29420 |
Transdiagnostic Cognitive Biomarkers |
| NEUR-2021-30029 |
Minnesota Neurogenetics Repository |
| NEUR-2021-30334 |
PRECISE |
| NEUR-2021-30478 |
Comparison of Anti-coagulation and anti-Platelet Therapies for Intracranial Vascular
Atherostenosis |
| NEUR-2022-30942 |
Natural History Study for DNA Repair Disorders |
| NEUR-2022-31003 |
Neuroplasticity in REM Sleep Behavior Disorder |
| NEUR-2022-31174 |
Defining Clinical Endpoints in LGMD |
| NEUR-2022-31334 |
Defining Endpoints in Becker Muscular Dystrophy |
| NEUR-2023-32286 |
Multimodal profiling of response to pediatric Comprehensive Behavioral Intervention
for Tics |
| NEUR-2023-32484 |
Identification of Prodromal Neurodegeneration in Serotonergic-Induced REM sleep Behavior
Disorder |
| NEUR-2024-32971 |
Biorepository to Support ALS Research in Minnesota |
| NEUR-2024-33465 |
ASSESS ALL ALS Study |
| NEUR-2024-33466 |
PREVENT ALL ALS |
| NEUR-2026-34547 |
Department of Neurology Movement Disorders Research Registry |
| NEURO-2020-28994 |
FVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial |
| NEURO-2022-30954 |
Feasibility of transcranial focused ultrasound to target brain tumor |
| NEURO-2022-31075 |
Telefitting spinal cord Stimulation for Pain - The TSP Study |
| NEURO-2022-31385 |
Extracranial Venous Narrowing in Headache and Dizziness |
| NEUROSURG-2021-29717 |
Improving Spinal Cord Stimulation with ECAP |
| NEUROSURG-2024-33254 |
Feasibility of Precision Functional Mapping for Pre-Surgical Planning |
| NEUROSURG-2024-33443 |
Duration of Dual Anti-Platelet Therapy after Flow Diversion of Unruptured Aneurysms |
| NEUROSURG-2025-34412 |
The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple
Sclerosis: A Pilot Study |
| NSU-2022-30582 |
Trigeminal Evoked Responses to Improve Rhizotomy |
| NSU-2023-28275 |
Molecular profiling of neurosurgical and otolaryngological diseases |
| NSU-2024-33331 |
Precision functional and structural mapping using DTI and rs-fMRI in hydrocephalus
patients undergoing endoscopic third ventriculostomy |
| OBGYN-2020-29359 |
iELEVATE |
| OBGYN-2022-31532 |
The University of Minnesota Perinatal Health Repository |
| OBGYN-2023-32442 |
Environmental influences on Child Health Outcomes
(ECHO) Cohort Data and Biospecimen Collection
Protocol |
| OBGYN-2025-33912 |
Use of CA125 and Complementary biomarkers for the early detection of Ovarian Cancer
in Low Risk Women (ID01-022) |
| OBGYN-2025-34329 |
Navigating Gender-Affirming Care: Barriers and Protective Factors for TGD Individuals
Traveling for out- of-state care |
| OBGYN-2025-34330 |
A sexual health pilot for engaging and responding to assigned-male-at-birth patients
(SPERM) |
| OPH-2022-30605 |
Topical Ice-therapy for pain modulation during Intravitreal Injections: A prospective
randomized control trial |
| OPH-2022-31305 |
A Phase III, Multicenter, Randomized, Double Masked, Placebo-Controlled Study of the
Efficacy and Safety of Oral N-Acetylcysteine in Patients with Retinitis Pigmentosa |
| OPH-2023-31727 |
Treatment of limbal stem cell deficiency with Descemet's membrane corneal on-lay |
| OPH-2024-32782 |
Investigating Losartan Effect on Glaucoma Filtration Surgery |
| OPH-2024-33337 |
A Phase 3 Randomized, Double-Masked, Placebo-Controlled Study to Investigate the Safety
and Efficacy of Oral Brepocitinib in Adults with Active, Non-Infectious Intermediate-,
Posterior-, and Panuveitis |
| OPH-2024-33447 |
Evaluating a novel 3-D printed double Maddox rod versus gold standard in the measurement
of torsional strabismus |
| OPH-2024-33536 |
A Double-Masked, Randomized, Placebo-Controlled, Paired-Eye Study to Evaluate the
Efficacy, Safety and Tolerability of Sepofarsen in Subjects with Leber Congenital
Amaurosis (LCA) due to the c.2991+1655A>G (p.Cys998X) Mutation in the CEP290 Gene |
| OPH-2025-33922 |
A Prospective, Open-label, Single-arm, Dose-escalation Study of the Safety and Tolerability
of a Single Subretinal Uniocular Injection of Allogeneic Induced Pluripotent Stem
Cell (iPSC)-derived Retinal Sheets (DSP-3077) in Adults with Retinitis Pigmentosa
(RP) |
| ORSU-2018-27173 |
A Prospective Multicenter Study Evaluating the Effect of Implant Material and/or Surface
Structure on Progression of Fusion in XLIF® Surgery |
| ORSU-2022-31524 |
Accuracy of Virtual versus Actual Trajectory in Pelvic Fixation Implant Placement
Using Intra-Operative Cone Beam CT (O-arm) and 3D Navigation |
| ORSU-2022-31554 |
Rod Unbending Force of Correction - Can We Predict How Much To Over-Bend? |
| ORTHOSURG-2024-33106 |
A Randomized Comparative Cohort Study of the Use of Intra-articular Corticosteroid
Injection Compared to Suprascapular Nerve Block for Treatment of Shoulder Pain |
| ORTHOSURG-2024-33151 |
A Comparative Study of the Biologic Tuberoplasty and Subacromial Balloon Spacer in
Treatment of Massive Irreparable Rotator Cuff Tears: Do they Reduce Bone-to-Bone Contact
Between the Tuberosity and Acromion? |
| OVNS-2019-28044 |
Research Study of the Anatomy of Eye Muscles |
| PACCS-2021-30269 |
myAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD patients in the home - a multi-center
randomized controlled trial |
| PACCS-2021-30431 |
Nintedanib Pharmacogenomics in Idiopathic Pulmonary Fibrosis (IPF) |
| PACCS-2022-30920 |
VX21-522-001: A Phase 1 Multiple Dose Escalation Study Evaluating the Safety and Tolerability
of VX-522 in Subjects 18 Years of Age and Older With Cystic Fibrosis and a CFTR Genotype
Not Responsive to CFTR Modulator Therapy |
| PACCS-2022-31207 |
The Lung Cell Study (TLC) |
| PACCS-2022-31232 |
The Blood Study (TB Study) |
| PACCS-2023-31589 |
LTx READY CF 2: A Multi-Site RCT: Lung Transplant Resources for Education And Decision-making
for Your CF 2 Study: A Multi-Site Randomized Controlled Clinical Trial |
| PACCS-2023-32172 |
Implementing Patient-Reported Outcome Measures (PROMs) to Assess Disease Impact and
Quality of Life in Sarcoidosis Patients |
| PACCS-2023-32267 |
Molecular Characterization of Progressive Pulmonary Sarcoidosis |
| PACCS-2023-32411 |
ABATE-IP-18: A Phase 1b, Multi-center Study of IV Gallium Nitrate in Patients with
Cystic Fibrosis who are Colonized with Nontuberculous Mycobacteria (The ABATE Study) |
| PACCS-2023-32418 |
Cystic Fibrosis Lung Transplant Consortium (CFLTC) Airway Brushings in CLAD Study |
| PACCS-2023-32430 |
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the
Efficacy and Safety of Inhaled Treprostinil in Subjects with Progressive Pulmonary
Fibrosis (TETON-PPF) |
| PACCS-2023-32485 |
A seamless, Phase 1b/2 multiple ascending dose/proof of concept study of XTMAB-16
in patients with pulmonary sarcoidosis with or without extrapulmonary manifestations |
| PACCS-2024-32693 |
COPDGene - Phase 4: GENETIC EPIDEMIOLOGY OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE |
| PACCS-2024-32807 |
Health Outcomes of Parents with Cystic Fibrosis (HOPe:CF) Aim 2 |
| PACCS-2024-33024 |
A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study Evaluating the Safety
and Efficacy of Pirfenidone Solution for Inhalation (AP01) in Subjects with Progressive
Pulmonary Fibrosis (PPF) |
| PACCS-2024-33033 |
Comparison of uncuffed endotracheal tube to no endotracheal tube in EBUS-TBNA procedure
under moderate sedation |
| PACCS-2024-33081 |
REACH-OB-23: A REsearch Study to Advance the CF THerapeutics Pipeline for People without
Modulators |
| PACCS-2024-33147 |
HUD - IBV Valve System, a Humanitarian Use Device for control of prolonged air leaks
under HDE H060002 |
| PACCS-2024-33426 |
CTOT-47: Belumosudil to BLOCK CLAD In High Risk Lung Transplant Recipients: A Randomized,
Multicenter, Double Blind, Placebo-Controlled Trial |
| PACCS-2025-33611 |
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety
of nerandomilast over at least 26 weeks in patients with Systemic Autoimmune Rheumatic
Diseases associated Interstitial Lung Diseases (SARD-ILD) |
| PACCS-2025-33621 |
Home-based Pulmonary Rehabilitation with Health Coaching in Patients with Fibrotic
Interstitial Lung Disease: A Prospective Pragmatic Randomized Waitlist-Controlled
Trial |
| PACCS-2025-33642 |
MOMENTOUS study (iMpact Of an ecg ai ModEl oN The diagnosis Of pUlmonary hypertenSion) |
| PACCS-2025-33676 |
VX23-828-001: A Phase 1 Study of VX-828 in Healthy Subjects and in Subjects with Cystic
Fibrosis |
| PACCS-2025-33876 |
MT2025-20: A Phase II, multi-part, five-year, randomized, open-label, assessor-blinded,
active-controlled, multicenter study to evaluate the efficacy and safety of rapcabtagene
autoleucel versus rituximab treatment in participants with severe refractory diffuse
cutaneous systemic sclerosis |
| PACCS-2025-34218 |
A double-blind, randomized, placebo-controlled, parallel group, Phase IIa trial to
evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics and efficacy
of BI 765423 administered intravenously on top of standard of care in patients with
idiopathic pulmonary fibrosis |
| PACCS-2025-34253 |
A Randomized, Controlled Multi-Center, Prospective Trial of Paclitaxel-Coated Pulmonary
Balloon for the Treatment of Benign Airway Stenosis (OXYGEN-RCT) |
| PEDS-2017-25993 |
Genetic and early life modifiers of NF1-related outcomes |
| PEDS-2017-26277 |
Outcomes and Survivorship in Pediatric Germ Cell Tumors |
| PEDS-2018-25868 |
PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis
Post-Transplant |
| PEDS-2018-27007 |
ALX-HPP-501: An Observational,Longitudinal Prospective, Long-term Registry of Patients
with Hypophosphatasia |
| PEDS-2019-27671 |
Integrating self-weighing at home to the clinical care of adolescents with obesity
who are seeking weight loss treatment |
| PEDS-2019-27867 |
A Multi-Center, Low lnterventional Study with a Retrospective Component in Participants
with Late Onset Pompe Disease |
| PEDS-2019-27873 |
A Phase I/II, Multicenter, Open-Label, Single-Dose, Dose-Ranging Study to Assess the
Safety and Tolerability of ST-920, a AAV2/6 Human Alpha Galactosidase A Gene Therapy,
in Subjects with Fabry Disease |
| PEDS-2019-28147 |
PediAtric ReseArch of Drugs, Immunoparalysis and Genetics during MODS (PARADIGM) |
| PEDS-2019-28291 |
Seizure disorder in cardiofaciocutaneous syndrome: Clinical characteristics, therapeutics
and impact on quality of life |
| PEDS-2020-28560 |
An Open-label, Phase 1/2 Study to Evaluate the Safety and Efficacy of Single-dose
PR001A in Infants with Type 2 Gaucher Disease |
| PEDS-2020-28571 |
A Descriptive Study of Child and Family Variables Related to Obesity in Autism Spectrum
Disorder |
| PEDS-2020-28768 |
CureGN: Cure Glomerulonephropathy Network
Version 3.0 |
| PEDS-2020-28885 |
A Phase 1/2 Open-Label, Multicenter, Dose Ranging and Confirmatory Study to Assess
the Safety, Tolerability and Efficacy of Single Dose of PBGM01 Delivered into the
Cisterna Magna of Pediatric Subjects Aged 1 to 24 Months with Type 1 (Infantile) and
Type 2a (Late Infantile) GM1 Gangliosidosis |
| PEDS-2020-29347 |
Improving Diagnosis and Treatment in Catecholaminergic Polymorphic Ventricular Tachycardia
(CPVT) |
| PEDS-2021-29482 |
ALL Childhood Heroes Assessment of Movement and Performance: Cardiac Fitness, Neuropathy
and Lung Function Among Survivors of Leukemia Through Exercise (FLASHLITE) |
| PEDS-2021-29635 |
Prospective Evaluation of Chronic Pancreatitis for Epidemiologic and Translational
Studies |
| PEDS-2021-29656 |
Neurodevelopmental outcomes in preterm infants with jaundice |
| PEDS-2021-29697 |
Self-Weighing for Weight Management in Adolescents Seeking Obesity Treatment: A Randomized
Pilot |
| PEDS-2021-29769 |
A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy,
and Pharmacokinetics of Sparsentan Treatment in Pediatric Subjects with Selected Proteinuric
Glomerular Diseases (EPPIK) |
| PEDS-2021-29867 |
Genomics of nephrotic syndrome and nephrotic syndrome/FSGS relapse after kidney transplantation
|
| PEDS-2021-29897 |
Diabetes RElated to Acute pancreatitis and its Mechanisms (DREAM) |
| PEDS-2021-30494 |
Personalized immunomodulation in pediatric sepsis-induced MODS (PRECISE) |
| PEDS-2022-29947 |
Maternal probiotic supplementation for improved neurodevelopmental outcomes in infants
of diabetic mothers (IDMs) |
| PEDS-2022-30889 |
Building Resilience in Adrenoleukodystrophy with Imaging and Neuropsychology (BRAIN) |
| PEDS-2022-31185 |
Assessment of Bone Age by BoneXpert Digital Analysis |
| PEDS-2022-31314 |
Optimizing Health Services for Youth Experiencing Homelessness |
| PEDS-2023-31392 |
Global Registry For Novel Therapies In Rare Bone & Endocrine Conditions |
| PEDS-2023-31716 |
Registry Study of Childhood Cancer in Minnesota |
| PEDS-2023-31753 |
Long-Term Follow-up of Fabry Disease Subjects who were Treated with ST-920, an AAV2/6
Human Alpha Galactosidase A Gene Therapy |
| PEDS-2023-31817 |
Pilot of standardized cognitive behavioral therapy for young adults with sickle cell
disease |
| PEDS-2023-31913 |
Pathogen Genomics Center of Excellence: Prospective Surveillance of Respiratory Pathogens
and Antimicrobial Resistance in Diverse Regional Populations (MINNE-LOVE-2) |
| PEDS-2023-31978 |
Establishing patient derived xenografts for MPNST |
| PEDS-2023-32113 |
A US Multi-center, Prospective, Non-interventional, Long-term, Effectiveness and Safety
Study of Patients Treated with SKYTROFA (lonapegsomatropin) (SkybriGHt) |
| PEDS-2023-32129 |
A Prospective, Non-interventional (NIS), Long-term, Post-Authorisation Safety Study
(PASS) of Patients Treated with Lonapegsomatropin (SkyPASS) |
| PEDS-2023-32163 |
A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to
evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of IV anifrolumab
in Pediatric Participants 5 to < 18 Years of Age with Moderate to
Severe Active Systemic Lupus Erythematosus While on Background Standard of Care Therapy |
| PEDS-2023-32381 |
Open-label, randomized, assessor-blinded, efficacy, safety, tolerability, and pharmacokinetics
study of subcutaneous risankizumab with an adalimumab reference arm in children with
active juvenile psoriatic arthritis (Study M23-732) |
| PEDS-2023-32510 |
SKoIRM-MN: Screening Kinesiology of Infants at Risk of Movement disorders |
| PEDS-2024-32318 |
A randomized, double-blind, placebo-controlled, multicenter study to evaluate the
safety, efficacy, and pharmacokinetics of budesonide extended-release tablets administered
once daily in pediatic subjects aged 5 to 17 years with active, mild to moderative
ulcerative colitis |
| PEDS-2024-32632 |
A Multicenter Multinational Observational Study of Children with
Hypochondroplasia |
| PEDS-2024-32753 |
A Phase 3, Open label, Uncontrolled Single-arm Study to Evaluate the Efficacy, Pharmacokinetics,
and Safety of Avacopan in Combination With a Rituximab or Cyclophosphamide-containing
Regimen in Children from 6 Years to less than 18 Years of Age with Active ANCA-associated
Vasculitis (AAV) |
| PEDS-2024-33020 |
A Phase 1, Open-label, Ascending Dose Study to Evaluate the Safety, Tolerability,
Efficacy, Pharmacokinetics and Pharmacodynamics of Recombinant Human Heparan N-Sulfatase
(rhHNS, GC1130A) Via Intracerebroventricular Access Device in Patients with Sanfilippo
Syndrome Type A (MPS IIIA). |
| PEDS-2024-33022 |
STOP PEDS RCT (Streamlined Treatment of Pulmonary Exacerbations in Pediatrics Randomized
Controlled Trial) |
| PEDS-2024-33045 |
A Phase 2, Randomized, Controlled, Multicenter Study of Vosoritide in Children With
Idiopathic Short Stature (ISS) |
| PEDS-2024-33091 |
Communication through Informal Interpreters among Somali families in the Neonatal
Intensive Care Unit |
| PEDS-2024-33115 |
A Phase 2, Randomized, Multicenter, Basket Study of Vosoritide in Children with Turner
Syndrome, Short Stature Homeobox-Containing Gene Deficiency, and Noonan Syndrome with
Inadequate Growth During or After Human Growth Hormone Treatment |
| PEDS-2024-33262 |
A pivotal Phase 3, multicenter, randomized, double-blind, placebo-controlled study
of the efficacy and safety of DMX-200 in patients with focal segmental glomerulosclerosis
(FSGS) who are receiving an angiotensin II receptor blocker (ARB) |
| PEDS-2024-33313 |
Voice Amplifier to Enhance Critical Care Coordination among Masked Providers |
| PEDS-2024-33452 |
Masonic Institute for the Developing Brain Positive Behavior Program |
| PEDS-2025-33681 |
Novel pneumothorax decompression device on a simulated model |
| PEDS-2025-33768 |
A Phase 1b/2a Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability,
Pharmacodynamics, and Efficacy of CNP-103 in Participants Ages 12-35 with Recent Onsetn
Stage 3 Type 1 Diabetes |
| PEDS-2025-33787 |
Baby ABS (Abdominal Binder Study) : Impact of Abdominal Binder Use on Abdominal Wall
Development in Premature Infants Requiring CPAP Support |
| PEDS-2025-33893 |
An Open-Label Multiple-Dose, 52-Week Study to Evaluate the Safety, Pharmacokinetics,
and Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents (ages: 12
to <18 years) with Conditions Associated with Deficiency or Absence of Endogenous
Testosterone Due to Primary or Secondary Hypogonadism (Congenital or Acquired) |
| PEDS-2025-33905 |
A Phase 2/3 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Atumelnant
Treatment in Pediatric Participants with Congenital Adrenal Hyperplasia Including
a Long-Term Extension |
| PEDS-2025-33920 |
A randomised, double-blind, placebo-controlled trial with an open-label extension
to assess the pharmacokinetics, safety, and efficacy of empagliflozin tablets in paediatric
patients with chronic kidney disease (EMPA-KIDNEY® Kids) |
| PEDS-2025-33943 |
Optimizing Pain Treatment In Children On Mechanical Ventilation |
| PEDS-2025-33978 |
A Multicenter, 12-Month, Randomized, Double Blind, Placebo-Controlled Phase 3 Efficacy
and Safety Study of Daily Oral LUM-201 in Naïve-to-Treatment, Prepubertal Children
with Growth Hormone Deficiency (GHD) |
| PEDS-2025-34011 |
Venglustat for Compassionate Use for Pediatric Gangliosidoses |
| PEDS-2025-34014 |
A Phase 1, Open-label, Single-arm Study to Evaluate the Pharmacokinetics
and Safety of Letermovir in Pediatric Kidney Transplant (KT) Recipients Less Than
18
Years of Age and Weighing Less Than 40 Kilograms |
| PEDS-2025-34068 |
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate
the Safety and Efficacy of Vosoritide in Infants and Young Children with Hypochondroplasia,
Aged 0 to < 36 Months |
| PEDS-2025-34073 |
Mitigating Health Disparities for Autism Identification in Somali Families in Minnesota |
| PEDS-2025-34160 |
Efficacy, safety, and pharmacokinetics of cargrilinitide s.c. 2.4 mg in combination
with semaglutide s.c. 2.4 mg (CagriSema) once weekly for weight management in children
and adolescents with overweight or obesity |
| PEDS-2025-34219 |
Early Identification of ASD in Females: Primary Care Screening of ASD - Parent and
Provider Interviews |
| PEDS-2025-34226 |
SGLT2i Therapy in Islet Transplantation (SIT) |
| PEDS-2025-34229 |
BUnderstanding the link between peripheral and brain-specific biomarkers of iron status |
| PEDS-2025-34339 |
Real world use of anti-obesity medications to treat adolescent obesity: moving beyond
the clinical |
| PEDS-2025-34411 |
Financial Toxicity of Chronic Pancreatitis: Assessing Healthcare Costs Pre and Post
Total Pancreatectomy with Islet Autotransplantation |
| PEDS-2025-34494 |
Neurodevelopmental Outcomes for CMV Infections Identified by Newborn Screening |
| PHARM-2021-31875 |
Extracellular Vesicles as Potential Biomarkers and Therapeutic Target in Gaucher Disease |
| PHARM-2023-32102 |
Pharmacogenomics to guide antidepressant selection in adolescents |
| PHARM-2024-32398 |
Go4PGx Locker Research Repository |
| PMR-2021-29617 |
Imaging of the Skin and Surrounding Tissue of Axillary Web Syndrome (AWS) and Lymphedema |
| PMR-2021-30243 |
Autonomic and Vascular Mechanisms of Cardiovascular Risk in Women with Post-traumatic
Stress-Disorder (PTSD) |
| PMR-2021-30275 |
Minnesota Regional SCIMS |
| PMR-2023-31801 |
Ecological Momentary Assessments to investigate causal relationships of factors that
influence chronic pain |
| PSYCH-2016-24287 |
Focus in NeuroDevelopment (FIND) Network: A Statewide Network for Research in Neurodevelopment |
| PSYCH-2018-27965 |
Outpatient Experiences in Mental Health Treatment |
| PSYCH-2019-27785 |
Individual Differences in Opioid use disorder |
| PSYCH-2019-28084 |
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the
Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No
Stimulation Control in Subjects With Treatment-Resistant Depression |
| PSYCH-2020-28579 |
Examining the Association between Social Cognitive Deficits and Suicidal Ideation
in Eating Disorders |
| PSYCH-2020-28582 |
Consortium of Psychosis Research Recruitment |
| PSYCH-2020-28714 |
Mechanistic Circuit Markers of Transcranial Magnetic Stimulation Outcomes in Pharmacoresistant
Depression |
| PSYCH-2020-28827 |
Neural Bases of Disgust Conditioning in Anorexia Nervosa |
| PSYCH-2020-28854 |
Neurobiological and Psychological Maintenance Mechanisms Associated with Anticipatory
Rewards in Bulimia Nervosa |
| PSYCH-2020-29302 |
Thinking and Reasoning – Online Testing (TAROT) |
| PSYCH-2021-30083 |
OCD DBS Registry |
| PSYCH-2021-30305 |
Visual Perception in Visual Snow Syndrome |
| PSYCH-2022-30611 |
The connection between Anxiety and Gastrointestinal Sensations in Individuals with
an Eating Disorder |
| PSYCH-2022-30910 |
tDCS and cognitive training as a neurodevelopmental intervention in FASD |
| PSYCH-2022-31484 |
TMS x Neureka |
| PSYCH-2023-31626 |
Technology Assisted Treatment for Binge Eating Disorder |
| PSYCH-2023-31860 |
Addressing Appetitive Traits to Promote Weight Management in Children who Overeat
(Family, Responsibility, Education, Support, and Health for food Responsiveness (FRESH-FR)) |
| PSYCH-2023-31938 |
Brain Training for Substance Use Disorders |
| PSYCH-2023-32483 |
Movie fMRI for Substance Use Disorders |
| PSYCH-2023-32508 |
Neural Mechanisms of Closed-loop Phase-locked Transcranial Magnetic Stimulation |
| PSYCH-2024-31551 |
tDCS and cognitive training for restrictive eating disorders |
| PSYCH-2024-32572 |
Computational Modeling of Tic Change Trajectories in Tourette Syndrome |
| PSYCH-2024-32713 |
Optimizing transcranial magnetic stimulation for stimulant use disorder |
| PSYCH-2024-32722 |
Investigating the Effects of VNS on Central Autonomic Network and Interoception |
| PSYCH-2024-32774 |
Autonomous Digital CBT Intervention for Opioid Use Disorder in Individuals with Co-Occurring
Internalizing Disorders |
| PSYCH-2024-33119 |
Validation of Flexible, Wearable Sensors to Detect and Monitor Tics |
| PSYCH-2024-33146 |
Identification of Optimal Stimulation Contacts through Cognitive Testing in Deep Brain
Stimulation for Psychiatric Indications |
| PSYCH-2024-33300 |
St. Louis Park Interventional Psychiatry Surgical Treatment Options Registry |
| PSYCH-2024-33393 |
Transcranial Magnetic Stimulation to Augment Behavior Therapy for Tics: R33 Phase |
| PSYCH-2024-33445 |
Precision Longitudinal Brain-Behavior Mechanisms of Adolescent Executive Function:
An Open Science MIDB Dataset |
| PSYCH-2024-33549 |
Feasibility Pilot of Accelerated Stimulation with TMS for Treatment of Major Depressive
Disorder (FAST-MDD) |
| PSYCH-2025-33599 |
Ethical Perspectives in Psychiatry |
| PSYCH-2025-33814 |
Optimizing Accelerated TMS for chronic pain with Thompson Sampling |
| PSYCH-2025-33827 |
COgnitive STrategies in Early Psychosis 1 |
| PSYCH-2025-33828 |
COgnitive STrategies in Early Psychosis 2 |
| PSYCH-2025-33885 |
Ultrasonic Neuromodulation of Cingulate Cortex for Fibromyalgia: A Blinded Randomized
Sham-Controlled Trial |
| PSYCH-2025-34165 |
Just-in-Time Training for Youth Mentors: A Strategy for Implementing Evidence-Based
Preventive Interventions for Youth in Rural Communities |
| PSYCH-2025-34246 |
Targeting Neuroplasticity for Persistent Post-Concussive Cognitive Symptoms: A Trial
of tDCS and Cognitive Training 3-12 Months Post-mTBI |
| PSYCH-2025-34493 |
Using MRI Scans to Inform Individualized Neuromodulation Interventions in Major Depressive
Disorders with and without Comorbidities |
| PSYCH-2025-34546 |
Precision Mapping of Diurnal Fluctuations in Brain Connectivity, Structure, and Physiological
Mechanisms |
| PSYCHOL-2017-33777 |
Dynamic Effects in Peripheral Auditory Processing |
| PSYCHOL-2017-33859 |
Studies of Complex Auditory Perception |
| PSYCHOL-2023-31867 |
Auditory Perception in Mild Cognitive Impairment |
| PSYCHOL-2024-33195 |
Effect of mild cognitive impairment on cortical processing of speech |
| PSYCHOL-2024-33418 |
Mechanisms of acquired hearing deficits |
| PSYCHOL-2025-33646 |
Neurobehavioral Impacts of Medical Cannabis Treatment in Chronic Pain Patients
Neurobehavioral Impacts of Medical Cannabis Use: An Observational Study |
| PSYCHOL-2025-33680 |
Neural Correlates of Goal Prioritization and Conscientiousness |
| PSYCHOL-2025-33745 |
State Representation in Early Psychosis 2 |
| PT-2018-27097 |
Autonomic regulation of blood pressure in premature and early menopausal women |
| PT-2021-29864 |
Vasomotor symptoms of menopause and cardiovascular disease: What is the link? |
| PT-2022-30683 |
Asymmetries in motor control and their impact on functional independence |
| PT-2022-30735 |
Diaphragmatic Breathing Exercises for post-COVID-19 Diaphragmatic Dysfunction (DD) |
| PT-2023-31814 |
D2D: Menopause perspectives and beliefs in the community |
| PT-2024-32330 |
Efficacy Verification in Early Diagnosis and Management of Lymphedema through Home
Body Water Analyzer |
| PT-2024-32769 |
Menopause Transition, Sex Hormone Deficiency and Autonomic and Vascular Function |
| PT-2025-33931 |
Altered cortical representation of paretic leg muscles in individuals with stroke:
a TMS-based motor mapping study |
| PT-2025-33965 |
Sensory, cognitive, motor interactions |
| PT-2025-34283 |
Feasibility of using an alternating pressure gradient system in athletes |
| PT-2025-34371 |
Role of Nitric Oxide (NO) in Endothelial Dysfunction in Premenopausal Women with Posttraumatic
Stress Disorder (PTSD) |
| RAD-2019-27687 |
The Neuronal Underpinnings of Non-invasive Laminar fMRI |
| RAD-2022-30567 |
Neurological Condition/Therapy Product Surveillance Registry (PSR) Platform Base |
| RAD-2022-31045 |
Vulnerability and Resiliency in the Aging Adult Brain Connectome (AABC) |
| RAD-2022-31520 |
Neural Pathways of Applied Reflexology |
| RAD-2024-33399 |
Individualized Mechanisms of Neural Plasticity and Response to Interventions in Neonates |
| RAD-2025-33751 |
Functional MRI of the human nose: an unprecedented investigational window into the
nervous system |
| RHEUM-2021-29914 |
CONQUER Protocol Number 001: COllaborative, National QUality and Efficacy Registry
for Tracking Disease Progression in Systemic Sclerosis (Scleroderma) Patients (CONQUER) |
| RHEUM-2024-33421 |
MT2024-43: A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics,
Pharmacodynamics, and Activity of Single Ascending Doses of SBT777101 in Subjects
with Rheumatoid Arthritis |
| SLP-2022-30630 |
Neural and Behavioral Markers of the Temporal Dynamics of Language Planning and Phonological
Working Memory Processes in Persons Who Stutter |
| SLP-2022-30685 |
Cochlear Implantation in Children with Asymmetric Hearing Loss or Single-Sided Deafness
Clinical Trial |
| SLP-2023-31730 |
Can spectral power and coherence reflect the integrity of the efferent cerebellar
cortical pathway in cerebellar mutism syndrome? |
| SLP-2023-32065 |
Developing Cancer Prevention Capacity through Community Health Workers |
| SLP-2024-33080 |
SMART Bottle Phase II
|
| SLP-2025-34239 |
Investigating EEG as a biomarker for tinnitus improvement after bimodal stimulation |
| SLP-2025-34396 |
Eye gaze patterns during audiovisual speech perception and natural conversation |
| SON-2021-29969 |
COCOA |
| SON-2021-30005 |
Efficacy and Mechanisms of Combined Aerobic Exercise and Cognitive Training in MCI
(The ACT Trial) |
| SON-2022-31447 |
Intermittent Pneumatic Compression with and without Exercise to Improve Functioning
in Peripheral Artery Disease: The INTERCEDE TRIAL |
| SON-2024-32760 |
Health Beliefs and Behaviors of Lung Cancer Screening in Chinese Americans |
| SON-2024-33577 |
BEETroot juice to reverse functional impairment in PAD: The BEET PAD Trial |
| SON-2025-33419 |
Care Partners and Patients Navigating Year 1 of Dyadic Self-Management post-LVAD |
| SON-2025-33721 |
Biometric and Ecological Momentary Assessment of Indicators of Relapse in Opioid Use
Disorder |
| SPH-2021-29712 |
Dissecting the role of acetaldehyde in oral carcinogenesis |
| SPH-2022-31233 |
Maternal Stress, Human Milk Composition, and Neurodevelopmental and Feeding Outcomes |
| SPH-2023-31237 |
Assessing and understanding the impacts of experiencing racism in adolescence on cardiovascular
disease risk markers in Twin Cities-based young adults |
| SPH-2023-31998 |
Using Natural Language Processing to determine long term functional outcomes of Stroke
patients |
| SPH-2023-32350 |
mGlide-Care: A mHealth Partnership with caregivers to improve HTN management in patients
with cognitive impairment |
| SPH-2024-33223 |
Electronic Nicotine Delivery Systems (ENDS) Use and Access in Florida's Tobacco Regulatory
Environment |
| SURG-2017-26057 |
A Randomized Trial of Intra-Portal Alone Versus Intra- and Extra- Portal Transplantation
of Pancreatic Islets After Total Pancreatectomy for Chronic Pancreatitis |
| SURG-2018-26636 |
Vertical Sleeve Gastrectomy and Lifestyle Modification for the Treatment of Non-Alcoholic
Steatohepatitis |
| SURG-2019-27532 |
Perspectives of HIV D+/R+ Transplant Recipients and Candidates |
| SURG-2021-29574 |
Pilot Study to Correlate Ultrasound with Computer Tomography Measurements of Sarcopenia
in Patients Undergoing Evaluation for Advanced Heart Failure Therapies |
| SURG-2021-30061 |
University of Minnesota Critical Care Pilot Biobase |
| SURG-2022-30801 |
Lung Transplant Clinical Center to Improve Surgical Outcomes |
| SURG-2022-31001 |
Save the Bottoms!!!: Assessing the Gay Male Experience with Anal Cancer Prevention
Strategies |
| SURG-2023-29833 |
An Open-Label, Pilot Clinical Trial To Test The Safety And Feasibility Of Intestinal
Microbiota Transplantation In Patients Undergoing Colon Resection |
| SURG-2023-31213 |
Research Evaluating Vagal Excitation and Anatomical Links |
| SURG-2023-31590 |
A DOSE ESCALATION AND PROOF-OF-CONCEPT STUDY OF REGN5459 OR REGN5458 (BCMA × CD3 BISPECIFIC
ANTIBODIES) FOR DESENSITIZATION OF CHRONIC KIDNEY DISEASE PATIENTS IN NEED OF KIDNEY
TRANSPLANTATION WHO ARE HIGHLY SENSITIZED TO HUMAN LEUKOCYTE ANTIGEN |
| SURG-2023-31628 |
High-Resolution Anoscopy Registry |
| SURG-2023-31841 |
Surgical Site Infections (SSI) and the Microbiome: Understanding the Pathogenesis
of SSI |
| SURG-2023-31889 |
Proteomics of Post-Operative Complications in Patients undergoing CABG |
| SURG-2023-32109 |
OCS Heart Perfusion (OHP-II) Registry |
| SURG-2023-32349 |
ltamiocel Compared to Placebo for Chronic Fecal Incontinence in Females with Obstetric
Injury (DigniFI) |
| SURG-2024-27972 |
New Patient-Centered Metric for Transplant Report Cards; Aim 1 |
| SURG-2024-32767 |
Prospective Multicenter Research on Donor and Recipient Management Strategies to Improve
Lung Transplant Outcomes |
| SURG-2024-32817 |
CMVIG prophylaxis in belatacept conversion kidney transplant recipients: a PK pilot
study |
| SURG-2024-33100 |
A PIVOTAL, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, MULTICENTER, INTERNATIONAL
PHASE III CLINICAL TRIAL TO INVESTIGATE THE EFFICACY AND SAFETY OF ALLO-APZ2-CVU ON
WOUND HEALING OF THERAPY-RESISTANT NON-HEALING
CHRONIC VENOUS ULCERS (CVU) |
| SURG-2024-33179 |
OCS Liver Perfusion (OLP-II) Registry |
| SURG-2024-33256 |
GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis Post-Approval Study |
| SURG-2024-33321 |
An Open-Label, Pilot Clinical Trial To Test The Efficacy Of A Suspension of Freeze-dried
Microbiota In Patients Undergoing Colon Resection |
| SURG-2024-33514 |
BESTOW-EXTENSION: A Phase 2, Multicenter, Open-Label Extension Study to Evaluate the
Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients |
| SURG-2025-32368 |
Atlas of Human Cardiac Anatomy: pediatric heart defects |
| SURG-2025-33649 |
Decision Making and Outcomes in Watch-and-Wait Management for Rectal Cancer |
| SURG-2025-33654 |
Prophylactic Reinforcement of Ventral Abdominal Incisions Trial (PREVENT): Prospective,
Multi-Center, Open-Label, Randomized, Controlled Trial of Phasix Mesh to Prevent Incisional
Hernia Subsequent to Open Midline Laparotomy |
| SURG-2025-33655 |
Continuation of a Home/Community-Based Anal Cancer Screening Unit and Protocol at
LGBTQ+ Focused Community Events |
| SURG-2025-33669 |
Investigation of a Novel, magNetically levitated VAD for the treatment of refractOry
left Ventricular heArT failurE (INNOVATE Trial) |
| SURG-2025-33677 |
Molecular Mechanisms of Post-injury SIRS |
| SURG-2025-33684 |
Renal Intervention for Chronic Hypertension Pilot Trial Using the Verve Medical RPDT
System |
| SURG-2025-33687 |
Artivion AMDS HDE Commercial Approval |
| SURG-2025-33855 |
Assessment of Breast and Nipple Sensation Following Nerve Grafting in DIEP Flap Breast
Reconstruction: A Prospective Study Using Two-Point Discrimination and Semmes-Weinstein
Monofilaments |
| SURG-2025-34070 |
Effects of colorectal surgery on the colonic microbiome and immune system |
| SURG-2025-34191 |
Molecular Mechanisms of Vascular Remodeling in Pulmonary Hypertension |
| SURG-2025-34559 |
Collection and Use of Human Saphenous Vein for Study of Sepsis and Other States of
Endothelial Dysfunction |
| SURG-2026-34545 |
Establishing Virtual Fit for a Durable Magnetically Levitated Bearingless Fail-Safe
Right Ventricular Assist Device |
| SURG-2026-34749 |
Single Patient Compassionate Use of Autologous iPSC-Derived Myogenic Progenitors (C3-automyo)
for the Treatment of LGMDR1/LGMD2A |
| URO-2023-31695 |
A phase III, single-arm study to evaluate the efficacy and safety of ONCOFID-P-B (paclitaxel-hyaluronic
acid conjugate) administered intravesically to patients with BCG- unresponsive Carcinoma
in Situ of the bladder with or without Ta-T1 papillary disease |
| URO-2023-32133 |
Prophylactic Antibiotic Use to Prevent Urinary Tract Infection Following Radical Cystectomy
and Urinary Diversion: Randomized Clinical Trial |
| URO-2023-32134 |
Ostomy Simulation for Patient Education Prior to Urologic Bowel Diversion Surgeries
|
| URO-2023-32437 |
Comparison of motor and sensory thresholds for sacral neuromodulation |
| URO-2024-33540 |
Testicular tissue cryopreservation for fertility preservation in patients facing infertility-causing
diseases or treatment regimens. |
| URO-2024-33637 |
Support for Transgender and Non-Binary Individuals Seeking Vaginoplasty (STRIVE) Study |
| URO-2025-33695 |
Bladder Management Patient Reported Outcomes for Young Adults with Spina Bifida |
| URO-2025-34126 |
Cell free and circulating tumor DNA in the management of muscle invasive bladder
cancer, a prospective cohort study. |
| VETMD-2020-28606 |
Histological assessment of osteochondritis dissecans specimens |
| VETMD-2020-28867 |
Histological assessment of osteochondritis dissecans biopsies |
| VETMD-2022-30178 |
Magnetic Resonance Imaging of Osteonecrosis of the Femoral Head |